US20150270498A1 - Condensed cyclic compound and organic light-emitting device comprising the same - Google Patents

Condensed cyclic compound and organic light-emitting device comprising the same Download PDF

Info

Publication number
US20150270498A1
US20150270498A1 US14/558,491 US201414558491A US2015270498A1 US 20150270498 A1 US20150270498 A1 US 20150270498A1 US 201414558491 A US201414558491 A US 201414558491A US 2015270498 A1 US2015270498 A1 US 2015270498A1
Authority
US
United States
Prior art keywords
group
substituted
salt
formula
fluorenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US14/558,491
Other versions
US9831443B2 (en
Inventor
Eun-young Lee
Young-Kook Kim
Jun-Ha Park
Sung-Soo Bae
Eun-Jae Jeong
Seok-Hwan Hwang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samsung Display Co Ltd
Original Assignee
Samsung Display Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samsung Display Co Ltd filed Critical Samsung Display Co Ltd
Assigned to SAMSUNG DISPLAY CO., LTD. reassignment SAMSUNG DISPLAY CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAE, SUNG-SOO, HWANG, SEOK-HWAN, Jeong, Eun-Jae, KIM, YOUNG-KOOK, LEE, EUN-YOUNG, PARK, JUN-HA
Publication of US20150270498A1 publication Critical patent/US20150270498A1/en
Application granted granted Critical
Publication of US9831443B2 publication Critical patent/US9831443B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • H01L51/0073
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/02Use of particular materials as binders, particle coatings or suspension media therefor
    • C09K11/025Use of particular materials as binders, particle coatings or suspension media therefor non-luminescent particle coatings or suspension media
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • H01L51/0054
    • H01L51/0058
    • H01L51/0067
    • H01L51/0072
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/615Polycyclic condensed aromatic hydrocarbons, e.g. anthracene
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/615Polycyclic condensed aromatic hydrocarbons, e.g. anthracene
    • H10K85/622Polycyclic condensed aromatic hydrocarbons, e.g. anthracene containing four rings, e.g. pyrene
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/615Polycyclic condensed aromatic hydrocarbons, e.g. anthracene
    • H10K85/626Polycyclic condensed aromatic hydrocarbons, e.g. anthracene containing more than one polycyclic condensed aromatic rings, e.g. bis-anthracene
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/649Aromatic compounds comprising a hetero atom
    • H10K85/654Aromatic compounds comprising a hetero atom comprising only nitrogen as heteroatom
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/649Aromatic compounds comprising a hetero atom
    • H10K85/657Polycyclic condensed heteroaromatic hydrocarbons
    • H10K85/6572Polycyclic condensed heteroaromatic hydrocarbons comprising only nitrogen in the heteroaromatic polycondensed ring system, e.g. phenanthroline or carbazole
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/649Aromatic compounds comprising a hetero atom
    • H10K85/657Polycyclic condensed heteroaromatic hydrocarbons
    • H10K85/6574Polycyclic condensed heteroaromatic hydrocarbons comprising only oxygen in the heteroaromatic polycondensed ring system, e.g. cumarine dyes
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1029Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
    • C09K2211/1033Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom with oxygen
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1044Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms
    • C09K2211/1048Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms with oxygen
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1059Heterocyclic compounds characterised by ligands containing three nitrogen atoms as heteroatoms
    • C09K2211/1062Heterocyclic compounds characterised by ligands containing three nitrogen atoms as heteroatoms with oxygen
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1088Heterocyclic compounds characterised by ligands containing oxygen as the only heteroatom
    • H01L51/5056
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • H10K50/10OLEDs or polymer light-emitting diodes [PLED]
    • H10K50/14Carrier transporting layers
    • H10K50/16Electron transporting layers

Definitions

  • One or more embodiments of the present disclosure relate to a condensed cyclic compound and an organic light-emitting device including the same.
  • An organic light-emitting device may have a structure in which a first electrode, a hole transport region, an emission layer, an electron transport region, and a second electrode are sequentially disposed in this order on a substrate. Holes injected from the first electrode move to the emission layer via the hole transport region, while electrons injected from the second electrode move to the emission layer via the electron transport region. Carriers such as the holes and electrons recombine in the emission layer to generate exitons. When the exitons drop from an excited state to a ground state, light is emitted.
  • One or more embodiments of the present disclosure include a novel condensed cyclic compound and an organic light-emitting device including the same.
  • X 1 is O or S
  • L 1 is selected from a substituted or unsubstituted C 3 -C 10 cycloalkylene group, a substituted or unsubstituted C 2 -C 10 heterocycloalkylene group, a substituted or unsubstituted C 3 -C 10 cycloalkenylene group, a substituted or unsubstituted C 2 -C 10 heterocycloalkenylene group, a substituted or unsubstituted C 6 -C 60 arylene group, a substituted or unsubstituted C 2 -C 60 heteroarylene group, a substituted or unsubstituted divalent nonaromatic condensed polycyclic group, and a substituted or unsubstituted divalent nonaromatic condensed heteropolycyclic group;
  • a1 is selected from 0, 1, 2, and 3;
  • R 1 to R 22 are each independently selected from a group represented by Formula 2-1, a group represented by Formula 2-2, a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C 1 -C 60 alkyl group, a substituted or unsubstituted C 2 -C 60 alkenyl group, a substituted or unsubstituted C 2 -C 60 alkynyl group, a substituted or unsubstituted C 1 -C 60 alkoxy group, a substituted or unsubstituted C 3 -C 10 cyclo
  • R 1 to R 10 is a group represented by Formula 2-1 or 2-2, and at least one of R 11 to R 22 is a group represented by Formula 2-1 or 2-2;
  • b1 is an integer selected from 1 to 3;
  • b2 is an integer selected from 1 to 5;
  • * in Formulae 2-1 and 2-2 is a binding site with a core represented by Formula 1A or Formula 1B;
  • R 31 , R 32 , Q 1 to Q 7 , Q 11 to Q 17 , Q 21 to Q 27 , and Q 31 to Q 37 are each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 60 alkyl group, a C 2 -C 60 alkenyl group, a C 2 -C 60 alkynyl group, a C 1 -C 60 alkoxy group, a C 3 -C 10 cycloalkyl group, a C 2 -C 10 heterocycloalkyl group, a C 3 -C 10 cycl
  • an organic light-emitting device includes: a first electrode; a second electrode disposed opposite to the first electrode; and an organic layer disposed between the first electrode and the second electrode and including an emission layer, wherein the organic layer includes at least one of the condensed cyclic compounds of Formula 1A or 1B described above.
  • FIG. 1 is a schematic view of a structure of an organic light-emitting device according to an embodiment of the present disclosure.
  • a condensed cyclic compound represented by Formula 1A or 1B wherein at least one of R 1 to R 10 in Formula 1A is a group represented by Formula 2-1 or a group represented by Formula 2-2, and at least one of R 11 to R 22 in Formula 1B is a group represented by Formula 2-1 or a group represented by Formula 2-2:
  • the condensed cyclic compounds of Formulae 1A and 1B may each independently include at least one of the group of Formula 2-1 and the group of Formula 2-2 as a substituent.
  • * is a binding site with carbon in a pyrene backbone of a pyrene core of Formula 1A or with carbon in a chrysene backbone of a chrysene core of Formula 1B.
  • X 1 may be O or S.
  • X 1 may be O, but is not limited thereto.
  • L 1 may be selected from a substituted or unsubstituted C 3 -C 10 cycloalkylene group, a substituted or unsubstituted C 2 -C 10 heterocycloalkylene group, a substituted or unsubstituted C 3 -C 10 cycloalkenylene group, a substituted or unsubstituted C 2 -C 10 heterocycloalkenylene group, a substituted or unsubstituted C 6 -C 60 arylene group, a substituted or unsubstituted C 2 -C 60 heteroarylene group, a substituted or unsubstituted divalent nonaromatic condensed polycyclic group, and a substituted or unsubstituted divalent nonaromatic condensed heteropolycyclic group.
  • L 1 may be selected from
  • L 1 may be represented by one of Formulae 3-1 to 3-32:
  • Y may be O, S, C(Z 3 )(Z 4 ), N(Z 5 ), or Si(Z 6 )(Z 7 );
  • Z 1 to Z 7 may be each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino groups, a hydrazine, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 20 alkyl group, a C 1 -C 20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group,
  • d1 may be an integer selected from 1 to 4
  • d2 may be an integer selected from 1 to 3
  • d3 may be an integer selected from 1 to 6
  • d4 may be an integer selected from 1 to 8
  • d5 may be 1 or 2
  • d6 may be an integer selected from 1 to 5
  • * and *′ may be binding sites with adjacent atoms.
  • L 1 may be represented by one of Formulae 4-1 to 4-23.
  • embodiments of the present disclosure are not limited thereto:
  • * and *′ may be binding sites with adjacent atoms.
  • a1 may be selected from 0, 1, 2, and 3.
  • a1 in Formulae 2-1 and 2-2 may be 0 or 1.
  • (L 1 ) a1 - may be a single bond.
  • a plurality of L 1 s may be identical to or different from each other.
  • R 1 to R 22 may be each independently selected from a group represented by Formula 2-1, a group represented by Formula 2-2, a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C 1 -C 60 alkyl group, a substituted or unsubstituted C 2 -C 60 alkenyl group, a substituted or unsubstituted C 2 -C 60 alkynyl group, a substituted or unsubstituted C 1 -C 60 alkoxy group, a substituted or unsubstituted
  • R 1 to R 10 may be a group represented by Formula 2-1 or 2-2, and at least one of R 1 to R 22 may be a group represented by Formula 2-1 or 2-2.
  • At least one substituent of R 1 to R 10 in Formula 1A, except for the groups represented by Formulae 2-1 and Formula 2-2, and at least one substituent of R 1 to R 22 in Formula 1B, except for the groups represented by Formulae 2-1 and Formula 2-2, may be each independently an electron transport moiety selected from a substituted or unsubstituted C 2 -C 20 heteroaryl group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group.
  • At least one substituent of R 1 to R 10 in Formula 1A, except for the groups represented by Formulae 2-1 and Formula 2-2, and at least one substituent of R 11 to R 22 in Formula 1B, except for the groups represented by Formulae 2-1 and Formula 2-2, may be each independently selected from a substituted or unsubstituted C 2 -C 20 heteroaryl group including at least one N as a ring-forming element, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group including at least one N as a ring-forming element.
  • embodiments of the present disclosure are not limited thereto.
  • At least one substituent of R 1 to R 10 in Formula 1A, except for the groups represented by Formulae 2-1 and Formula 2-2, and at least one substituent of R 11 to R 22 in Formula 1B, except for the groups represented by Formulae 2-1 and Formula 2-2, may be each independently selected from
  • R 1 to R 22 may be each independently selected from
  • a group represented by Formula 2-1 a group represented by Formula 2-2, a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 20 alkyl group, and a C 1 -C 20 alkoxy group,
  • Q 3 to Q 5 may be each independently selected from a C 1 -C 20 alkyl group, a C 1 -C 20 alkoxy group, a phenyl group, and a nahthyl group;
  • R 1 to R 10 may be a group represented by Formula 2-1 or Formula 2-2, and at least one of R 11 to R 22 may be a group represented by Formula 2-1 or Formula 2-2.
  • R 1 to R 22 may be each independently selected from
  • a group represented by Formula 2-1 a group represented by Formulae 2-2, hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 20 alkyl group, and a C 1 -C 20 alkoxy group,
  • Q 3 to Q 5 may be each independently selected from a C 1 -C 20 alkyl group, a C 1 -C 20 alkoxy group, a phenyl group, and a nahthyl group;
  • R 1 to R 10 may be a group represented by Formula 2-1 or Formula 2-2, and at least one of R 11 to R 22 may be a group represented by Formula 2-1 or Formula 2-2.
  • R 1 or R 2 in Formula 1A may be a group represented by Formula 2-1 or Formula 2-2.
  • one of R 1 to R 10 in Formula 1A, and one of R 11 to R 22 in Formula 1B may be a group represented by Formula 2-1 or Formula 2-2.
  • the pyrene backbone of the pyrene core represented by Formula 1A may include only one of the group of Formula 2-1 and the group of Formula 2-2 as a substituent
  • the chrysene backbone of the chrysene core represented by Formula 1B may include only one of the group of Formula 2-1 and the group of Formula 2-2 as a substituent.
  • R 1 to R 22 in Formulae 1A and 1B may be each independently selected from a group of Formula 2-1, a group of Formula 2-2, a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 20 alkyl group, a C 1 -C 20 alkoxy group, Si(Q 3 )(Q 4 )(Q 5 ) (where Q 3 to Q 5 may be each independently selected from a C 1 -C 20 alkyl group, a C 1 -C 20 alkoxy group, a phenyl group, and a naphthyl group),
  • R 31 and R 32 in Formulae 2-1 and 2-2 may be each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 60 alkyl group, a C 2 -C 60 alkenyl group, a C 2 -C 60 alkynyl group, a C 1 -C 60 alkoxy group, a C 3 -C 10 cycloalkyl group, a C 2 -C 10 heterocycloalkyl group, a C 3 -C 10 cycloalkenyl group, a C 2 -C 10 heterocycloo
  • R 31 and R 32 in Formulae 2-1 and 2-2 may be each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 20 alkyl group, a C 1 -C 20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a
  • R 31 and R 32 in Formulae 2-1 and 2-2 may be each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 10 alkyl group, and a C 1 -C 10 alkoxy group.
  • R 31 and R 32 in Formulae 2-1 and 2-2 may be both hydrogens.
  • b1 which indicates the number of R 31 s, may be an integer selected from 1 to 3.
  • b1 number of R 31 s may be identical to or different from each other.
  • b2 which indicates the number of R 32 s, may be an integer selected from 1 to 5.
  • b2 number of R 32 s may be identical to or different from each other.
  • the group of Formula 2-1 may be selected from groups represented by Formulae 2-1(1), 2-1(2), and 2-1(3), and the group of Formula 2-2 may be selected from groups represented by Formulae 2-2(1) and 2-2(2).
  • embodiments of the present disclosure are not limited thereto:
  • X 1 , L 1 , a 1 , R 31 , R 32 , b1, and b2 may be the same as those defined above, and thus detailed descriptions thereof will be omitted here.
  • the “substituted monovalent non-aromatic condensed heteropolycyclic group” for R 1 to R 22 may exclude the group of Formula 2-1 and the group of Formula 2-2.
  • the condensed cyclic compound of Formula 1A may be represented by one of Formulae 1A-1 to 1A-4, and the condensed cyclic compound of Formula 1B may be represented by one of Formulae 1B-1 and 1B-2:
  • X 1 , L 1 , a1, R 6 , R 7 , R 31 , R 32 , b1, and b2 may be the same as those defined herein.
  • the condensed cyclic compound of Formula 1A may be represented by one of Formulae 1A-1(1), 1A-1(2), 1A-2(1), 1A-2(2), 1A-3(1), 1A-3(2), 1A-3(3), 1A-4(1), and 1A-4(2)
  • the condensed cyclic compound of Formula 1B may be represented by one of Formulae 1B-1(1), 1B-1(2), 1B-1(3), 1B-2(1), and 1B-2(2):
  • X 1 , L 1 , a1, R 6 , R 7 , R 16 , R 31 , R 32 , b1, and b2 may be the same as those defined herein.
  • the condensed cyclic compound of Formula 1A or Formula 1B may be represented by one of Formulae 1A-1(1), 1A-1(2), 1A-2(1), 1A-2(2), 1A-3(1), 1A-3(2), 1A-3(3), 1A-4(1), 1A-4(2), 1B-1(1), 1B-1(2), 1B-1(3), 1B-2(1), and 1B(2), wherein, in Formulae 1A-1(1), 1A-1(2), 1A-2(1), 1A-2(2), 1A-3(1), 1A-3(2), 1A-3(3), 1A-4(1), 1A-4(2), 1B-1(1), 1B-1(2), 1B-1(3), 1B-2(1), and 1B(2),
  • L 1 may be selected from groups represented by Formulae 3-1 to 3-32 (for example, groups represented by Formulae 4-1 to 4-23);
  • a1 may be 0 or 1;
  • R 6 , R 7 , and R 16 may be selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 20 alkyl group, a C 1 -C 20 alkoxy group, Si(Q 3 )(Q 4 )(Q 5 ) (where Q 3 to Q 5 may be each independently selected from a C 1 -C 20 alkyl group, a C 1 -C 20 alkoxy group, a phenyl group, and a naphthyl group), and the groups represented by Formulae 5-1 to 5-35;
  • R 3 and R 32 may be each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 10 alkyl group, and a C 1 -C 10 alkoxy group; and
  • b1 and b2 may be an integer selected from 1 to 3. However, embodiments of the present disclosure are not limited thereto.
  • the condensed cyclic compound of Formula 1 may be one of Compounds 1A to 133A and Compounds 1B to 92B.
  • At least one of R 1 to R 10 in Formula 1A may be a group of Formula 2-1 or a group of Formula 2-2, at least one of R 1 to R 22 in Formula 1B may be a group of Formula 2-1 or a group of Formula 2-2. Since the groups of Formulae 2-1 and 2-2 have essentially include “—CN (a cyano group)” as a substituent, the condensed cyclic compounds represented by Formulae 1A and 1B may have improved charge transport characteristics, improved emission characteristic, and a high glass transition temperature.
  • an organic light-emitting device including at least one of the condensed cyclic compounds of Formulae 1A and 1B may have enhanced heat resistance against a Joule heat generated between organic layers or between an organic layer and an electrode under high-temperature environments, during storage and/or operation, and thus may have improved lifetime characteristics.
  • an organic light-emitting device including at least one of the condensed cyclic compounds represented by Formulae 1A and 1B above may have a low driving voltage, a high luminance, a high efficiency, and a long lifetime.
  • the at least one of the condensed cyclic compounds of Formula 1A and 1B may be synthesized using a known organic synthesis method. Methods of synthesizing the condensed cyclic compounds of Formula 1 may be understood by those of ordinary skill in the art based on the examples that will be described below.
  • the at least one of the condensed cyclic compounds of Formula 1A and 1B may be used between a pair of electrodes of the organic light-emitting device.
  • the at least one of the condensed cyclic compounds of Formula 1A and 1B may be in an electron transport region, for example, in an electron transport layer.
  • an organic light-emitting device includes a first electrode, a second electrode disposed opposite to the first electrode, and an organic layer disposed between the first electrode and the second electrode and including an emission layer, wherein the organic layer includes at least one of the condensed cyclic compounds of Formula 1A and 1B described above.
  • the organic layer) including at least one condensed cyclic compound means that “(the organic layer) including one of the condensed cyclic compounds of Formulae 1A and 1B, or at least two different condensed cyclic compounds of Formula 1A and 1B.”
  • the organic layer may include only Compound 1A as the condensed cyclic compound.
  • Compound 1A may be present in the electron transport layer of the organic light-emitting device.
  • the organic layer may include Compounds 1A and 2A as the condensed cyclic compounds.
  • Compounds 1A and 2A may be present both in the same layer (for example, in the electron transport layer) or may be present in different layers (for example, in the emission layer and the electron transport layer, respectively).
  • the organic layer may include i) a hole transport region disposed between the first electrode (anode) and the emission layer and including at least one of a hole injection layer, a hole transport layer, a buffer layer, and an electron blocking layer; and ii) an electron transport region disposed between the emission layer and the second electrode (cathode) and including at least one of a hole blocking layer, an electron transport layer, and an electron injection layer.
  • the electron transport region may include at least one of the condensed cyclic compounds of Formulae 1A and 1B.
  • the electron transport region may include the electron transport layer, wherein the electron transport layer may include the at least one of the condensed cyclic compounds of Formulae 1A and 1B.
  • organic layer refers to a single layer and/or a plurality of layers disposed between the first and second electrodes of the organic light-emitting device.
  • a material in the “organic layer” is not limited to an organic material.
  • FIG. 1 is a schematic sectional view of an organic light-emitting device 10 according to an embodiment of the present disclosure.
  • the organic light-emitting device 10 includes a first electrode 110 , an organic layer 150 , and a second electrode 190 .
  • a substrate may be disposed under the first electrode 110 or on the second electrode 190 in FIG. 1 .
  • the substrate may be a glass or transparent plastic substrate with good mechanical strength, thermal stability, transparency, surface smoothness, ease of handling, and water resistance.
  • the first electrode 110 may be formed by depositing or sputtering a first electrode-forming material on the substrate 11 .
  • a material having a high work function may be used as the first electrode-forming material to facilitate hole injection.
  • the first electrode 110 may be a reflective electrode, a semi-transmissive electrode, or a transmissive electrode.
  • Transparent and conductive materials such as ITO, IZO, SnO 2 , and ZnO may be used to form the first electrode.
  • the first electrode 110 as a semi-transmissive electrode or a reflective electrode may comprise at least one material selected from magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), and magnesium-silver (Mg—Ag).
  • the first electrode 110 may have a single-layer structure or a multi-layer structure including a plurality of layers.
  • the first electrode 110 may have a three-layered structure of ITO/Ag/ITO, but is not limited thereto.
  • the organic layer 150 may be disposed on the first electrode 110 .
  • the organic layer 150 may include an emission layer (EML).
  • EML emission layer
  • the organic layer 150 may include a hole transport region disposed between the first electrode and the EML, and an electron transport region between the EML and the second electrode.
  • the hole transport region may include at least one of a hole injection layer (HIL), a hole transport layer (HTL), a buffer layer, and an electron blocking layer (EBL).
  • HIL hole injection layer
  • HTL hole transport layer
  • EBL electron blocking layer
  • the electron transport layer may include at least one of a hole blocking layer (HBL), an electron transport layer (ETL), and an electron injection layer (EIL).
  • HBL hole blocking layer
  • ETL electron transport layer
  • EIL electron injection layer
  • the hole transport region may have a single-layered structure including a single material, a single-layered structure including a plurality of materials, or a multi-layered structure including a plurality of layers including different materials.
  • the electron transport region may have a single-layered structure including a plurality of materials, or a multi-layered structure of HIL/HTL, HIL/HTL/buffer layer, HIL/buffer layer, HTL/buffer layer, or HIL/HTL/EBL, wherein these layers forming a multi-layered structure are sequentially disposed on the first electrode 110 in the order stated above.
  • HIL/HTL HIL/HTL/buffer layer
  • HIL/buffer layer HTL/buffer layer
  • HIL/HTL/EBL HIL/HTL/EBL
  • the HIL may be formed on the first electrode 110 by using any of a variety of methods, for example, by using vacuum deposition, spin coating, casting, Langmuir-Blodgett (LB) deposition, inkjet printing, laser printing, laser induced thermal imaging (LITI), or the like.
  • vacuum deposition spin coating, casting, Langmuir-Blodgett (LB) deposition, inkjet printing, laser printing, laser induced thermal imaging (LITI), or the like.
  • LB Langmuir-Blodgett
  • LITI laser induced thermal imaging
  • the deposition conditions may vary depending on the material that is used to form the HIL and the structure of the HIL.
  • the deposition conditions may be selected from the following conditions: a deposition temperature of about 100° C. to about 500° C., a degree of vacuum of about 10 ⁇ 8 to about 10 ⁇ 3 torr, and a deposition rate of about 0.01 to 100 ⁇ /sec.
  • the coating conditions may vary depending on the material that is used to form the HIL and the structure of the HIL.
  • the coating conditions may be selected from the following conditions: a coating rate of about 2,000 rpm to about 5,000 5 pm and a heat treatment temperature of about 800° C. to about 200° C.
  • the HTL may be formed on the first electrode 110 or the HIL by using any of a variety of methods, for example, by using vacuum deposition, spin coating, casting, Langmuir-Blodgett (LB) deposition, inkjet printing, laser printing, laser induced thermal imaging (LITI), or the like.
  • LB Langmuir-Blodgett
  • LITI laser induced thermal imaging
  • the conditions for deposition and coating may be similar to the above-described deposition and coating conditions for forming the HIL, and accordingly will not be described in detail.
  • the hole transport region may include at least one of m-MTDATA, TDATA, 2-TNATA, NPB, ⁇ -NPB, TPD, Spiro-TPD, Spiro-NPB, ⁇ -NPB, TAPC, HMTPD, 4,4′,4′′-tris(N-carbazolyl)triphenylamine (TCTA), polyaniline/dodecylbenzene sulfonic acid (Pani/DBSA), poly(3,4-ethylenedioxythiophene)/poly(4-styrenesulfonate)(PEDOT/PSS), polyaniline/camphor sulfonic acid (Pani/CSA), polyaniline/poly(4-styrenesulfonate) (PANI/PSS), a compound represented by Formula 201 below, and a compound represented by Formula 202 below.
  • TCTA 4,4′,4′′-tris(N-carbazolyl)triphenylamine
  • TCTA 4,4′
  • L 201 to L 205 may be each independently defined as described above in conjunction with L 1 in Formula 1;
  • xa1 to xa4 are each independently selected from 0, 1, 2, and 3;
  • xa5 may be selected from 1, 2, 3, 4, and 5;
  • R 201 to R 204 may be each independently selected from a substituted or unsubstituted C 3 -C 10 cycloalkyl group, a substituted or unsubstituted C 2 -C 10 heterocycloalkyl group, a substituted or unsubstituted C 3 -C 10 cycloalkenyl group, a substituted or unsubstituted C 2 -C 10 heterocycloalkenyl group, a substituted or unsubstituted C 6 -C 60 aryl group, a substituted or unsubstituted C 6 -C 60 aryloxy group, a substituted or unsubstituted C 6 -C 60 arylthio group, a substituted or unsubstituted C 2 -C 60 heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted monovalent non-aromatic condensed
  • L 201 to L 205 may be each independently
  • xa1 to xa4 may be each independently 0, 1, or 2;
  • xa5 may be 1, 2, or 3;
  • R 201 to R 204 may be each independently,
  • the compound of Formula 201 may be represented by Formula 201A:
  • the compound of Formula 201 may be represented by Formula 201A-1, but is not limited thereto:
  • the compound of Formula 202 may be represented by Formula 202A, but is not limited thereto:
  • L 201 to L 203 , xa1 to xa3, xa5, and R 202 to R 204 may be defined as described in conjunction with Formula 201;
  • R 211 may be defined as described in conjunction with R 203 in Formula 201;
  • R 213 to R 216 may be each independently a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 60 alkyl group, a C 2 -C 60 alkenyl group, a C 2 -C 60 alkynyl group, a C 1 -C 60 alkoxy group, a C 1 -C 10 cycloalkyl group, a C 2 -C 10 heterocycloalkyl group, a C 3 -C 10 cycloalkenyl group, a C 2 -C 10 heterocycloalkenyl group, a C 6 -
  • L 201 to L 203 may be each independently
  • xa1 to xa3 may be each independently 0 or 1,
  • R 203 , R 211 , and R 212 may be each independently
  • R 213 and R 214 may be each independently
  • a C 1 -C 20 alkyl group or a C 1 -C 20 alkoxy group each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridin
  • R 215 and R 216 may be each independently
  • F, —Cl, —Br, —I a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 20 alkyl group, or a C 1 -C 20 alkoxy group;
  • a C 1 -C 20 alkyl group or a C 1 -C 20 alkoxy group each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridin
  • xa5 may be 1 or 2.
  • R 213 and R 214 may be linked to each other to form a saturated or unsaturated ring.
  • the compound represented by Formula 201, and the compound represented by Formula 202 may be compounds HT1 to HT20 illustrated below, but are not limited thereto.
  • a thickness of the hole transport region may be from about 100 ⁇ to about 10000 ⁇ , and in some embodiments, from about 100 ⁇ to about 1000 ⁇ .
  • a thickness of the HIL may be from about 100 ⁇ to about 10,000 ⁇ , and in some embodiments, from about 100 ⁇ to about 1,000 ⁇ , and a thickness of the HTL may be from about 50 ⁇ to about 2,000 ⁇ , and in some embodiments, from about 100 ⁇ to about 1,500 ⁇ .
  • the thicknesses of the hole transport region, the HIL, and the HTL are within these ranges, satisfactory hole transport characteristics may be obtained without a substantial increase in driving voltage.
  • the hole transport region may further include a charge-generating material to improve conductivity, in addition to the materials as described above.
  • the charge-generating material may be homogeneously or inhomogeneously dispersed in the hole transport region.
  • the charge-generating material may be, for example, a p-dopant.
  • the p-dopant may be one of quinine derivatives, metal oxides, and compounds with a cyano group, but is not limited thereto.
  • Non-limiting examples of the p-dopant are quinone derivatives such as tetracyanoquinonedimethane (TCNQ), 2,3,5,6-tetrafluoro-tetracyano-1,4-benzoquinonedimethane (F4-TCNQ), and the like, metal oxides such as tungsten oxide, molybdenum oxide, and the like; and Compound HT-D1 below.
  • the hole transport region may further include at least one of a buffer layer and an EBL, in addition to the HIL and HTL described above.
  • the buffer layer may compensate for an optical resonance distance of light according to a wavelength of the light emitted from the EML, and thus may improve light-emission efficiency.
  • a material in the buffer layer may be any material used in the hole transport region.
  • the EBL may block migration of electrons from the electron transport region into the EML.
  • the EML may be formed on the first electrode 110 or the hole transport region by using any of a variety of methods, for example, by using vacuum deposition, spin coating, casting, Langmuir-Blodgett (LB) deposition, inkjet printing, laser printing, laser induced thermal imaging (LITI), or the like.
  • LB Langmuir-Blodgett
  • LITI laser induced thermal imaging
  • the deposition and coating conditions for forming the EML may be similar to the above-described deposition and coating conditions for forming the HIL, and accordingly will not be described in detail.
  • the EML may be patterned into a red emission layer, a green emission layer, and a blue emission layer to correspond to individual subpixels, respectively.
  • the EML may have a structure in which a red emission layer, a green emission layer and a blue emission layer are stacked upon one another, or a structure including a mixture of a red light-emitting material, a green light-emitting material, and a blue light-emitting material, and thus may emit white light.
  • the EML may include a host and a dopant.
  • the host may include at least one of TPBi, TBADN, ADN (also referred to as “DNA”), CBP, CDBP, and TCP.
  • TPBi TPBi
  • TBADN TBADN
  • ADN also referred to as “DNA”
  • CBP CBP
  • CDBP CDBP
  • TCP TCP
  • the host may include a compound represented by Formula 301.
  • Ar 301 may be
  • L 301 may be defined as described above in conjunction with L 201 in Formula 201,
  • R 301 may be
  • xb1 may be selected from 0, 1, 2, and 3;
  • xb2 may be selected from 1, 2, 3, and 4.
  • L 301 may be
  • a phenylene group a naphthylene group, a fluorenylene group, a spiro-fluorenylene group, a benzofluorenylene group, a dibenzofluorenylene group, a phenanthrenylene group, an anthracenylene group, a pyrenylene group, or a chrysenylene group; or
  • R 301 may be
  • a C 1 -C 20 alkyl group or a C 1 -C 20 alkoxy group each substituted at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, and a chrysenyl group;
  • a phenyl group a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, or a chrysenyl group;
  • the host may include a compound represented by Formula 301A:
  • the compound of Formula 301 may include at least one of Compounds H1 to 42, but is not limited thereto:
  • the host may include at least one of Compounds H43 to H49, but is not limited thereto:
  • the dopant may include at least one of a fluorescent dopant and a phosphorescent dopant.
  • the phosphorescent dopant may include an organometallic complex represented by Formula 401:
  • M may be selected from iridium (Ir), platinum (Pt), osmium (Os), titanium (Ti), zirconium (Zr), hafnium (Hf), europium (Eu), terbium (Tb), and thulium (Tm);
  • X 401 to X 404 may be each independently a nitrogen or a carbon
  • rings A 401 and A 402 may be each independently selected from a substituted or unsubstituted benzene, a substituted or unsubstituted naphthalene, a substituted or unsubstituted fluorene, a substituted or unsubstituted spiro-fluorene, a substituted or unsubstituted indene, a substituted or unsubstituted pyrrole, a substituted or unsubstituted thiophene, a substituted or unsubstituted furan, a substituted or unsubstituted imidazole, a substituted or unsubstituted pyrazole, a substituted or unsubstituted thiazole, a substituted or unsubstituted isothiazole, a substituted or unsubstituted oxazole, a substituted or unsubstituted isoxazole, a substituted or unsubsti
  • the substituted benzene at least one substituent of the substituted benzene, the substituted naphthalene, the substituted fluorene, the substituted spiro-fluorene, the substituted indene, the substituted pyrrole, the substituted thiophene, the substituted furan, the substituted imidazole, the substituted pyrazole, the substituted thiazole, the substituted isothiazole, the substituted oxazole, the substituted isoxazole, the substituted pyridine, the substituted pyrazine, the substituted pyrimidine, the substituted pyridazine, the substituted quinoline, the substituted isoquinoline, the substituted benzoquinoline, the substituted quinoxaline, the substituted quinazoline, the substituted carbazole, the substituted benzoimidazole, the substituted benzofuran, the substituted benzothiophene, the substituted isobenzothiophene,
  • a deuterium —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 60 alkyl group, a C 2 -C 60 alkenyl group, a C 2 -C 60 alkynyl group, and C 1 -C 60 alkoxy group;
  • L 401 may be an organic ligand
  • xc1 may be 1, 2, or 3;
  • xc2 may be 0, 1, 2, or 3.
  • L 401 may be a monovalent, divalent, or trivalent organic ligand.
  • L 401 in Formula 401 may be selected from a halogen ligand (for example, Cl or F), a diketone ligand (for example, acetylacetonate, 1,3-diphenyl-1,3-propanedionate, 2,2,6,6-tetramethyl-3,5-heptanedionate, or hexafluoroacetonate), a carboxylic acid ligand (for example, picolinate, dimethyl-3-pyrazolecarboxylate, or benzoate), a carbon monoxide ligand, an isonitrile ligand, a cyano ligand, and a phosphorous ligand (for example, phosphine or phosphite).
  • a halogen ligand for example, Cl or F
  • a diketone ligand for example, acetylacetonate, 1,3-
  • a 401 in Formula 401 has at least two substituent groups
  • the at least two substituent groups of A 401 may be linked to each other to form a saturated or unsaturated ring.
  • a 402 in Formula 401 has at least two substituents groups
  • the at least two substituent groups of A 402 2 may be linked to each other to form a saturated or unsaturated ring.
  • a 401 and A 402 may be linked to A 401 and A 402 of another adjacent ligand, respectively, directly or via a linking group (for example, a C 1 -C 5 alkylene group, —N(R′)— (where R′ is a C 1 -C 10 alkyl group or a C 6 -C 20 aryl group), or C( ⁇ O)—).
  • a linking group for example, a C 1 -C 5 alkylene group, —N(R′)— (where R′ is a C 1 -C 10 alkyl group or a C 6 -C 20 aryl group), or C( ⁇ O)—).
  • the fluorescent dopant may include at least one of Compounds PD1 to PD74, but is not limited thereto.
  • the phosphorescent dopant may include PtOEP:
  • the fluorescent dopant may further include at least one of DPAVBi, BDAVBi, TBPe, DCM, DCJTB, Coumarin 6, and C545T.
  • the fluorescent dopant may include a compound represented by Formula 501:
  • Ar 501 may be selected from
  • L 501 to L 503 may be the same as those for L 201 defined herein;
  • R 501 and R 502 may be each independently selected from
  • xd1 to xd3 may be each independently selected from 0, 1, 2, and 3;
  • xb4 may be selected from 1, 2, 3, and 4.
  • the fluorescent host may include at least one of Compounds FD1 to FD8:
  • An amount of the dopant in the EML may be from about 0.01 parts to about 15 parts by weight based on 100 parts by weight of the host, but is not limited to this range.
  • the thickness of the EML may be about 100 ⁇ to about 1000 ⁇ , and in some embodiments, may be from about 200 ⁇ to about 600 ⁇ . When the thickness of the EML is within these ranges, the EML may have good light emitting ability without a substantial increase in driving voltage.
  • the electron transport region may be disposed on the EML.
  • the electron transport region may include at least one of a HBL, an ETL, and an EIL.
  • a HBL a bit line
  • ETL an electrostatic layer
  • EIL an electrostatic layer
  • the electron transport region may have a structure including an ETL/EIL, or a HBL/ETL/EIL, wherein the layers forming a structure of the electron transport region may be sequentially stacked on the EML in the order stated above.
  • ETL/EIL ETL/EIL
  • HBL/ETL/EIL HBL/ETL/EIL
  • the organic layer 150 of the organic light-emitting device 10 may include the electron transport region between the EML and the second electrode 190 , and at least one of the condensed cyclic compounds of Formulae 1A and 1B may be in the electron transport region.
  • the electron transport region may include a HBL.
  • the HBL may prevent diffusion of triplet exitons or holes into the ETL from the EML.
  • the HBL may be formed on the EML by using any of a variety of methods, for example, by using vacuum deposition, spin coating, casting, Langmuir-Blodgett (LB) deposition, inkjet printing, laser printing, laser induced thermal imaging (LITI), or the like.
  • LB Langmuir-Blodgett
  • LITI laser induced thermal imaging
  • the deposition and coating conditions for forming the HBL may be similar to the above-described deposition and coating conditions for forming the HIL, and accordingly will not be described in detail.
  • the HBL may include at least one of BCP below and Bphen below.
  • embodiments of the present disclosure are not limited thereto.
  • a thickness of the HBL may be from about 20 ⁇ to about 1,000 ⁇ , and in some embodiments, from about 30 ⁇ to about 300 ⁇ . When the thickness of the HBL is within these ranges, the HBL may have improved hole blocking ability without a substantial increase in driving voltage.
  • the electron transport region may include an ETL.
  • the ETL may be formed on the EML or the HBL by using any of a variety of methods, for example, by using vacuum deposition, spin coating, casting, Langmuir-Blodgett (LB) deposition, inkjet printing, laser printing, laser induced thermal imaging (LITI), or the like.
  • LB Langmuir-Blodgett
  • LITI laser induced thermal imaging
  • the deposition and coating conditions for forming the ETL may be similar to the above-described deposition and coating conditions for forming the HIL, and accordingly will not be described in detail.
  • the organic layer 150 of the organic light-emitting device may include an electron transport region between the EML and the second electrode 190 , wherein the electron transport region may include an ETL, and the ETL may include at least one of the condensed cyclic compounds of Formulae 1A and 1B.
  • the ETL may further include at least one of BCP, Bphen Alq 3 , Balq, TAZ, and NTAZ, in addition to the at least one of the condensed cyclic compounds of Formulae 1A and 1B.
  • a thickness of the ETL may be from about 100 ⁇ to about 1,000 ⁇ , and in some embodiments, from about 150 ⁇ to about 500 ⁇ . When the thickness of the ETL is within these ranges, the ETL may have satisfactory electron transporting ability without a substantial increase in driving voltage.
  • the ETL may further include a metal-containing material, in addition to the above-described materials.
  • the metal-containing material may include a lithium (Li) complex.
  • Li complex Non-limiting examples of the Li complex are compound ET-D1 below (lithium quinolate (LiQ)), or compound ET-D2.
  • the electron transport region may include an EIL that may facilitate injection of electrons from the second electrode 190 .
  • the EIL may be formed on the ETL by using any of a variety of methods, for example, by using vacuum deposition, spin coating, casting, Langmuir-Blodgett (LB) deposition, inkjet printing, laser printing, laser induced thermal imaging (LITI), or the like.
  • LB Langmuir-Blodgett
  • LITI laser induced thermal imaging
  • the deposition and coating conditions for forming the EIL may be similar to the above-described deposition and coating conditions for forming the HIL, and accordingly will not be described in detail.
  • the EIL may include at least one selected from LiF, NaCl, CsF, Li 2 O, BaO, and LiQ.
  • a thickness of the EIL may be from about 1 ⁇ to about 100 ⁇ , and in some embodiments, from about 3 ⁇ to about 90 ⁇ . When the thickness of the EIL is within these ranges, the EIL may have satisfactory electron injection ability without a substantial increase in driving voltage.
  • the second electrode 190 may be disposed on the organic layer 150 , as described above.
  • the second electrode 190 may be a cathode as an electron injecting electrode.
  • a material for forming the second electrode 190 may be a metal, an alloy, an electrically conductive compound, which have a low-work function, or a mixture thereof.
  • Non-limiting examples of materials for forming the second electrode 190 are lithium (Li), magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), and magnesium-silver (Mg—Ag).
  • a material for forming the second electrode 190 may be ITO or IZO.
  • the second electrode 190 may be a reflective electrode, a semi-transmissive electrode, or a transmissive electrode.
  • a C 1 -C 60 alkyl group refers to a linear or branched aliphatic hydrocarbon monovalent group having 1 to 60 carbon atoms.
  • Non-limiting examples of the C 1 -C 60 alkyl group a methyl group, a ethyl group, a propyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an iso-amyl group, and a hexyl group.
  • a C 1 -C 60 alkylene group refers to a divalent group having the same structure as the C 1 -C 60 alkyl.
  • a C 1 -C 60 alkoxy group refers to a monovalent group represented by —OA 101 (where A 101 is a C 1 -C 60 alkyl group as described above.
  • a 101 is a C 1 -C 60 alkyl group as described above.
  • Non-limiting examples of the C 1 -C 60 alkoxy group are a methoxy group, an ethoxy group, and an isopropyloxy group.
  • a C 2 -C 60 alkenyl group refers to a hydrocarbon group including at least one carbon double bond in the middle or terminal of the C 2 -C 60 alkyl group.
  • Non-limiting examples of the C 2 -C 60 alkenyl group are an ethenyl group, a prophenyl group, and a butenyl group.
  • a C 2 -C 60 alkylene group refers to a divalent group having the same structure as the C 2 -C 60 alkenyl group.
  • a C 2 -C 60 alkynyl group refers to a hydrocarbon group including at least one carbon triple bond in the middle or terminal of the C 2 -C 60 alkyl group.
  • Non-limiting examples of the C 2 -C 60 alkynyl group are an ethynyl group and a propynyl group.
  • a C 2 -C 60 alkynylene group used herein refers to a divalent group having the same structure as the C 2 -C 60 alkynyl group.
  • a C 3 -C 10 cycloalkyl group refers to a monovalent, monocyclic hydrocarbon group having 3 to 10 carbon atoms.
  • Non-limiting examples of the C 3 -C 10 cycloalkyl group are a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a cycloheptyl group.
  • a C 3 -C 10 cycloalkylene group refers to a divalent group having the same structure as the C 3 -C 10 cycloalkyl group.
  • a C 2 -C 10 heterocycloalkyl group refers to a monovalent monocyclic group having 2 to 10 carbon atoms in which at least one hetero atom selected from N, O, P, and S is included as a ring-forming atom.
  • Non-limiting examples of the C 2 -C 10 heterocycloalkyl group are a tetrahydrofuranyl group and a tetrahydrothiophenyl group.
  • a C 2 -C 10 heterocycloalkylene group refers to a divalent group having the same structure as the C 2 -C 10 heterocycloalkyl group.
  • a C 3 -C 10 cycloalkenyl group refers to a monovalent monocyclic group having 3 to 10 carbon atoms that includes at least one double bond in the ring but does not have aromacity.
  • Non-limiting examples of the C 3 -C 10 cycloalkenyl group are a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group.
  • a C 3 -C 10 cycloalkenylene group refers to a divalent group having the same structure as the C 3 -C 10 cycloalkenyl group.
  • a C 2 -C 10 heterocycloalkenyl group used herein refers to a monovalent monocyclic group having 2 to 10 carbon atoms that includes at least one double bond in the ring and in which at least one hetero atom selected from N, O, P, and S is included as a ring-forming atom.
  • Non-limiting examples of the C 2 -C 10 heterocycloalkenyl group are a 2,3-hydrofuranyl group and a 2,3-hydrothiophenyl group.
  • a C 2 -C 10 heterocycloalkenylene group used herein refers to a divalent group having the same structure as the C 3 -C 10 heterocycloalkenyl group.
  • a C 6 -C 60 aryl group refers to a monovalent, aromatic carbocyclic aromatic group having 6 to 60 carbon atoms
  • a C 6 -C 60 arylene group refers to a divalent, aromatic carbocyclic group having 6 to 60 carbon atoms.
  • Non-limiting examples of the C 6 -C 60 aryl group are a phenyl group, a naphthyl group, an anthracenyl group, a phenanthrenyl group, a pyrenyl group, and a chrysenyl group.
  • the C 6 -C 60 aryl group and the C 6 -C 60 arylene group include at least two rings, the rings may be fused to each other.
  • a C 2 -C 60 heteroaryl group refers to a monovalent, aromatic carbocyclic aromatic group having 2 to 60 carbon atoms in which at least one hetero atom selected from N, O, P, and S is included as a ring-forming atom, and 2 to 60 carbon atoms.
  • a C 2 -C 60 heteroarylene group refers to a divalent, aromatic carbocyclic group having 2 to 60 carbon atoms in which at least one hetero atom selected from N, O, P, and S is included as a ring-forming atom.
  • Non-limiting examples of the C 2 -C 60 heteroaryl group are a pyridinyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, and an isoquinolinyl group.
  • the C 2 -C 60 heteroaryl and the C 2 -C 60 heteroarylene include at least two rings, the rings may be fused to each other.
  • a C 6 -C 60 aryloxy group indicates —OA 102 (where A 102 is a C 6 -C 60 aryl group as described above), and a C 6 -C 60 arylthio group indicates —SA 103 (where A 103 is a C 6 -C 60 aryl group as described above).
  • a monovalent non-aromatic condensed polycyclic group refers to a monovalent group having at least two rings condensed to each other, in which only carbon atoms (for example, 8 to 60 carbon atoms) are exclusively included as ring-forming atoms and the entire molecule has non-aromacity.
  • a non-limiting example of the monovalent non-aromatic condensed polycyclic group is a fluorenyl group.
  • a divalent non-aromatic condensed polycyclic group refers to a divalent group having the same structure as the monovalent non-aromatic condensed polycyclic group.
  • a monovalent non-aromatic condensed heteropolycyclic group refers to a monovalent group having at least two rings condensed to each other, in which carbon atoms (for example, 2 to 60 carbon atoms) and a hetero atom selected from N, O. P, and S are as ring-forming atoms and the entire molecule has non-aromacity.
  • a non-limiting example of the monovalent non-aromatic condensed heteropolycyclic group is a carbazolyl group.
  • a divalent non-aromatic condensed heteropolycyclic group refers to a divalent group having the same structure as the monovalent non-aromatic condensed heteropolycyclic group.
  • a deuterium —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 60 alkyl group, a C 2 -C 60 alkenyl group, a C 2 -C 60 alkynyl group, and a C 1 -C 60 alkoxy group,
  • Q 1 to Q 7 , Q 11 to Q 17 , Q 21 to Q 27 , and Q 31 to Q 37 may be each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 60 alkyl group, a C 2 -C 60 alkenyl group, a C 2 -C 60 alkynyl group, a C 1 -C 60 alkoxy group, a C 3 -C 10 cycloalkyl group, a C 2 -C 10 heterocycloalkyl group, a C 3 -C 100 cycloalkenyl group,
  • a deuterium —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 60 alkyl group, a C 2 -C 60 alkenyl group, a C 2 -C 60 alkynyl group, and a C 1 -C 60 alkoxy group,
  • a cyclopentyl group a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexcenyl group, a phenyl group, a pentalenyl group, an indenyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenyl
  • a cyclopentyl group a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexcenyl group, a phenyl group, a pentalenyl group, an indenyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenyl
  • Q 1 to Q 7 , Q 11 to Q 17 , Q 21 to Q 27 , and Q 31 to Q 37 may be each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 60 alkyl group, a C 2 -C 60 alkenyl group, a C 2 -C 60 alkynyl group, a C 1 -C 60 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohex
  • Ph used herein refers to phenyl
  • Me used herein refers to methyl
  • Et used herein refers to ethyl
  • ter-Bu or “Bu t ” used herein refers to tert-butyl
  • Compound 32A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-32A instead of 1-pyrene boronic acid was used.
  • Compound 39A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-29 and Intermediate I-39A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Intermediate I-29 was synthesized in the same manner as in the synthesis of Intermediate I-7, Intermediate I-8, Intermediate I-9, and Intermediate I-10 of Synthesis Example 2, except that 2-bromo-5-chloro-1-iodobenzene, instead of 2-bromo-4-chloro-1-iodobenzene, was used.
  • Compound 46A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-20 and Intermediate I-46A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Compound 51A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-13 and Intermediate I-15A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Compound 62A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-10 and Intermediate I-62A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Compound 66A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-10 and Intermediate I-66A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Compound 81A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-13 and Intermediate I-81A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Compound 85A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-29 and Intermediate I-85A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Compound 94A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-10 and Intermediate I-94A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Compound 109A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-20 and Intermediate I-109A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Compound 113A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-20 and Intermediate I-113A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Compound 112A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-20 and Intermediate I-122A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Compound 128A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-20 and Intermediate I-128A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Compound 131A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-29 and Intermediate I-119A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used to synthesize Compound 1A of Synthesis Example 1.
  • Compound 22B was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-20 and Intermediate I-22B, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Compound 32B was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-20 and Intermediate I-32B, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Compound 85A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-10 and Intermediate I-79B, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • a corning 15 ⁇ /cm 2 (1200 ⁇ ) ITO glass substrate was cut to a size of 50 mm ⁇ 50 mm ⁇ 0.7 mm and then sonicated in isopropyl alcohol and pure water each for five minutes, and then cleaned by irradiation of ultraviolet rays for 30 minutes and exposure to ozone.
  • the resulting ITO glass substrate was mounted into a vacuum deposition device.
  • Compound 1A was deposited on the EML to form an ETL having a thickness of about 300 ⁇ , and then LiF was deposited on the ETL to form an EIL having a thickness of about 10 ⁇ . Then, Al was deposited on the EIL to form a cathode having a thickness of about 3000 ⁇ , thereby completing the manufacture of an organic light-emitting device.
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 3A instead of Compound 1A was used to form the ETL.
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 16A instead of Compound 1A was used to form the ETL.
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 24A instead of Compound 1A was used to form the ETL.
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 39A instead of Compound 1A was used to form the ETL.
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 51A instead of Compound 1A was used to form the ETL.
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 62A instead of Compound 1A was used to form the ETL.
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 72A instead of Compound 1A was used to form the ETL.
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 81A instead of Compound 1A was used to form the ETL.
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 113A instead of Compound 1A was used to form the ETL.
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 3B instead of Compound 1A was used to form the ETL.
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 13B instead of Compound 1A was used to form the ETL.
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 38B instead of Compound 1A was used to form the ETL.
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 79B instead of Compound 1A was used to form the ETL.
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Alq 3 instead of Compound 1A was used to form the ETL.
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound A instead of Compound 1 was used to form the ETL.
  • Driving voltages, current densities, luminances, efficiencies, and half-lifetimes of the organic light-emitting devices of Examples 1 to 14 and Comparative Examples 1 and 2 were evaluated using a Kethley Source-Measure Unit (SMU 236) and a PR650 (Spectroscan) Source Measurement Unit. (available from Photo Research, Inc.). The results are shown in Table 2 below. A half-lifetime was measured as the time taken until a measured initial luminance (assumed as 100%) is reduced to 50%.)
  • the organic light-emitting devices of Examples 1 to 14 were found to have lower driving voltages, improved current densities, improved luminances, improved efficiencies, and improved half-lifetimes, compared to those of the organic light-emitting devices of Comparative Examples 1 and 2.
  • an organic light-emitting device including a condensed cyclic compound of Formula 1 above may have a low driving voltage, a high efficiency, a high luminance, and a long lifetime.

Abstract

A condensed cyclic compound and an organic light-emitting device including the same are provided.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This application claims the benefit of Korean Patent Application No. 10-2014-0032165, filed on Mar. 19, 2014, in the Korean Intellectual Property Office, the disclosure of which is incorporated herein in its entirety by reference.
  • BACKGROUND
  • 1. Field
  • One or more embodiments of the present disclosure relate to a condensed cyclic compound and an organic light-emitting device including the same.
  • 2. Description of the Related Art
  • An organic light-emitting device may have a structure in which a first electrode, a hole transport region, an emission layer, an electron transport region, and a second electrode are sequentially disposed in this order on a substrate. Holes injected from the first electrode move to the emission layer via the hole transport region, while electrons injected from the second electrode move to the emission layer via the electron transport region. Carriers such as the holes and electrons recombine in the emission layer to generate exitons. When the exitons drop from an excited state to a ground state, light is emitted.
  • SUMMARY
  • One or more embodiments of the present disclosure include a novel condensed cyclic compound and an organic light-emitting device including the same.
  • Additional aspects will be set forth in part in the description which follows and, in part, will be apparent from the description, or may be learned by practice of the presented embodiments.
  • According to one or more embodiments of the present disclosure, there is provided a condensed cyclic compound represented by Formula 1A or 1B:
  • Figure US20150270498A1-20150924-C00001
  • wherein, in Formulae 1A, 1B, 2-1, and 2-2,
  • X1 is O or S;
  • L1 is selected from a substituted or unsubstituted C3-C10 cycloalkylene group, a substituted or unsubstituted C2-C10 heterocycloalkylene group, a substituted or unsubstituted C3-C10 cycloalkenylene group, a substituted or unsubstituted C2-C10 heterocycloalkenylene group, a substituted or unsubstituted C6-C60 arylene group, a substituted or unsubstituted C2-C60 heteroarylene group, a substituted or unsubstituted divalent nonaromatic condensed polycyclic group, and a substituted or unsubstituted divalent nonaromatic condensed heteropolycyclic group;
  • a1 is selected from 0, 1, 2, and 3;
  • R1 to R22 are each independently selected from a group represented by Formula 2-1, a group represented by Formula 2-2, a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C1-C60 alkyl group, a substituted or unsubstituted C2-C60 alkenyl group, a substituted or unsubstituted C2-C60 alkynyl group, a substituted or unsubstituted C1-C60 alkoxy group, a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C2-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, a substituted or unsubstituted C2-C10 heterocycloalkenyl group, a substituted or unsubstituted C6-C60 aryl group, a substituted or unsubstituted C6-C60 aryloxy group, a substituted or unsubstituted C6-C60 arylthio group, a substituted or unsubstituted C2-C60 heteroaryl group, a substituted or unsubstituted monovalent nonaromatic condensed polycyclic group, a substituted or unsubstituted monovalent nonaromatic condensed heteropolycyclic group, —N(Q1)(Q2), —Si(Q3)(Q4)(Q5), and —B(Q6)(Q7);
  • at least one of R1 to R10 is a group represented by Formula 2-1 or 2-2, and at least one of R11 to R22 is a group represented by Formula 2-1 or 2-2;
  • b1 is an integer selected from 1 to 3;
  • b2 is an integer selected from 1 to 5; and
  • * in Formulae 2-1 and 2-2 is a binding site with a core represented by Formula 1A or Formula 1B;
  • wherein at least one substituent of the substituted C3-C10 cycloalkylene group, the substituted C2-C10 heterocycloalkylene group, the substituted C3-C10 cycloalkenylene group, the substituted C2-C10 heterocycloalkenylene group, the substituted C6-C60 arylene group, the substituted C2-C60 heteroarylene group, the substituted divalent nonaromatic condensed polycyclic group, the substituted divalent nonaromatic condensed heteropolycyclic group, the substituted C1-C60 alkyl group, the substituted C2-C60 alkenyl group, the substituted C2-C60 alkynyl group, the substituted C1-C60 alkoxy group, the substituted C3-C10 cycloalkyl group, the substituted C2-C10 heterocycloalkyl group, the substituted C3-C10 cycloalkenyl group, the substituted C2-C10 heterocyclolalkenyl group, the substituted C6-C60 aryl group, the substituted C6-C60 aryloxy group, the substituted C6-C60 arylthio group, the substituted C2-C60 heteroaryl group, the substituted monovalent nonaromatic condensed polycyclic group, and the substituted monovalent nonaromatic condensed heteropolycyclic group is selected from
  • a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, and a C1-C60 alkoxy group, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, and a C1-C60 alkoxy group, each substituted with at least one of a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C3-C10cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C2-C60 heteroaryl group, a monovalent nonaromatic condensed polycyclic group, a monovalent nonaromatic condensed heteropolycyclic group, —N(Q11)(Q12), —Si(Q13)(Q14)(Q15), and —B(Q16)(Q17), a C3-C10 cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C2-C60 heteroaryl group, a monovalent nonaromatic condensed polycyclic group, and a monovalent nonaromatic condensed heteropolycyclic group, a C3-C10cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C2-C60 heteroaryl group, a monovalent nonaromatic condensed polycyclic group, and a monovalent nonaromatic condensed heteropolycyclic group, each substituted with at least one of a deuterium atom, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C10cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C2-C60 heteroaryl group, a monovalent nonaromatic condensed polycyclic group, a monovalent nonaromatic condensed heteropolycyclic group, —N(Q21)(Q22), —Si(Q23)(Q24)(Q25), and —B(Q26)(Q27), and —N(Q31)(Q32), —Si(Q33)(Q34)(Q35), and —B(Q36)(Q37),
  • wherein R31, R32, Q1 to Q7, Q11 to Q17, Q21 to Q27, and Q31 to Q37 are each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C10 cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C2-C60 heteroaryl group, a monovalent nonaromatic condensed polycyclic group, and a monovalent aromatic condensed heteropolycyclic group.
  • According to one or more embodiments of the present disclosure, an organic light-emitting device includes: a first electrode; a second electrode disposed opposite to the first electrode; and an organic layer disposed between the first electrode and the second electrode and including an emission layer, wherein the organic layer includes at least one of the condensed cyclic compounds of Formula 1A or 1B described above.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • These and/or other aspects will become apparent and more readily appreciated from the following description of the embodiments, taken in conjunction with the accompanying drawing in which:
  • FIG. 1 is a schematic view of a structure of an organic light-emitting device according to an embodiment of the present disclosure.
  • DETAILED DESCRIPTION
  • Reference will now be made in detail to embodiments, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to the like elements throughout. In this regard, the present embodiments may have different forms and should not be construed as being limited to the descriptions set forth herein. Accordingly, the embodiments are merely described below, by referring to the FIGURES, to explain aspects of the present description. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items. Expressions such as “at least one of,” when preceding a list of elements, modify the entire list of elements and do not modify the individual elements of the list.
  • According to an embodiment of the present disclosure, there is provided a condensed cyclic compound represented by Formula 1A or 1B, wherein at least one of R1 to R10 in Formula 1A is a group represented by Formula 2-1 or a group represented by Formula 2-2, and at least one of R11 to R22 in Formula 1B is a group represented by Formula 2-1 or a group represented by Formula 2-2:
  • Figure US20150270498A1-20150924-C00002
  • The condensed cyclic compounds of Formulae 1A and 1B may each independently include at least one of the group of Formula 2-1 and the group of Formula 2-2 as a substituent. In Formulae 2-1 and 2-2, * is a binding site with carbon in a pyrene backbone of a pyrene core of Formula 1A or with carbon in a chrysene backbone of a chrysene core of Formula 1B.
  • In Formulae 2-1 and 2-2, X1 may be O or S. For example, in Formulae 2-1 and 2-2, X1 may be O, but is not limited thereto.
  • In Formulae 2-1 and 2-2, L1 may be selected from a substituted or unsubstituted C3-C10cycloalkylene group, a substituted or unsubstituted C2-C10 heterocycloalkylene group, a substituted or unsubstituted C3-C10 cycloalkenylene group, a substituted or unsubstituted C2-C10 heterocycloalkenylene group, a substituted or unsubstituted C6-C60 arylene group, a substituted or unsubstituted C2-C60 heteroarylene group, a substituted or unsubstituted divalent nonaromatic condensed polycyclic group, and a substituted or unsubstituted divalent nonaromatic condensed heteropolycyclic group.
  • In some embodiments, in Formulae 2-1 and 2-2, L1 may be selected from
  • a phenylene group, a pentalenylene group, an indeylene group, a naphthylene group, an azulenylene group, a heptalenylene group, an indacenylene group, an acenaphthylene group, a fluorenylene group, a spiro-fluorenylene group, a benzofluorenylene group, a dibenzofluorenylene group, a phenalenylene group, a phenanthrenylene group, an anthracenylene group, a fluoranthenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylene group, a naphthacenylene group, a picenylene group, a perylenylene group, a pentaphenylene group, a hexacenylene group, a pentacenylene group, a rubicenylene group, a coronenylene group, an ovalenylene group, a pyrrolylene group, a thiophenylene group, a furanylene group, an imidazolylene group, a pyrazolylene group, a thiazolylene group, an isothiazolylene group, an oxazolylene group, an isooxazolylene group, a pyridinylene group, a pyrazinylene group, a pyrimidinylene group, a pyridazinylene group, an isoindolylene group, an indolylene group, an indazolylene group, a purinylene group, a quinolinylene group, an isoquinolinylene group, a benzoquinolinylene group, a phthalazinylene group, a naphthyridinylene group, a quinoxalinylene group, a quinazolinylene group, a cinnolinylene group, a carbazolylene group, a phenanthridinylene group, an acridinylene group, a phenanthrolinylene group, a phenazinylene group, a benzoimidazolylene group, a benzofuranylene group, a benzothiophenylene group, an isobenzothiazolylene group, a benzooxazolylene group, an isobenzooxazolylene group, a triazolylene group, a tetrazolylene group, an oxadiazolylene group, a triazinylene group, a dibenzofuranylene group, a dibenzothiophenylene group, a benzocarbazolylene group, a dibenzocarbazolylene group, a thiadiazolyene group, an imidazopyridinylene group, and an imidazopyrimidinylene group, a phenylene group, a pentalenylene group, an indeylene group, a naphthylene group, an azulenylene group, a heptalenylene group, an indacenylene group, an acenaphthylene group, a fluorenylene group, a spiro-fluorenylene group, a benzofluorenylene group, a dibenzofluorenylene group, a phenalenylene group, a phenanthrenylene group, an anthracenylene group, a fluoranthenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylene group, a naphthacenylene group, a picenylene group, a perylenylene group, a pentaphenylene group, a hexacenylene group, a pentacenylene group, a rubicenylene group, a coronenylene group, an ovalenylene group, a pyrrolylene group, a thiophenylene group, a furanylene group, an imidazolylene group, a pyrazolylene group, a thiazolylene group, an isothiazolylene group, an oxazolylene group, an isooxazolylene group, a pyridinylene group, a pyrazinylene group, a pyrimidinylene group, a pyridazinylene group, an isoindolylene group, an indolylene group, an indazolylene group, a purinylene group, a quinolinylene group, an isoquinolinylene group, a benzoquinolinylene group, a phthalazinylene group, a naphthyridinylene group, a quinoxalinylene group, a quinazolinylene group, a cinnolinylene group, a carbazolylene group, a phenanthridinylene group, an acridinylene group, a phenanthrolinylene group, a phenazinylene group, a benzoimidazolylene group, a benzofuranylene group, a benzothiophenylene group, an isobenzothiazolylene group, a benzooxazolylene group, an isobenzooxazolylene group, a triazolylene group, a tetrazolylene group, an oxadiazolylene group, a triazinylene group, a dibenzofuranylene group, a dibenzothiophenylene group, a benzocarbazolylene group, a dibenzocarbazolylene group, a thiadiazolyene group, an imidazopyridinylene group, and an imidazopyrimidinylene group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, an a C1-C20 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexenyl group, a phenyl group, a pentalenyl group, an indeyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluorantenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenyl group, a pycenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovalenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isooxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzooxazolyl group, an isobenzooxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a thiadiazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group.
  • In some embodiments, in Formulae 2-1 and 2-2, L1 may be represented by one of Formulae 3-1 to 3-32:
  • Figure US20150270498A1-20150924-C00003
    Figure US20150270498A1-20150924-C00004
    Figure US20150270498A1-20150924-C00005
    Figure US20150270498A1-20150924-C00006
  • In Formulae 3-1 to 3-32,
  • Y, may be O, S, C(Z3)(Z4), N(Z5), or Si(Z6)(Z7);
  • Z1 to Z7 may be each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino groups, a hydrazine, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group;
  • d1 may be an integer selected from 1 to 4, d2 may be an integer selected from 1 to 3, d3 may be an integer selected from 1 to 6, d4 may be an integer selected from 1 to 8, d5 may be 1 or 2, d6 may be an integer selected from 1 to 5, and * and *′ may be binding sites with adjacent atoms.
  • In some other embodiments, in Formulae 2-1 and 2-2, L1 may be represented by one of Formulae 4-1 to 4-23. However, embodiments of the present disclosure are not limited thereto:
  • Figure US20150270498A1-20150924-C00007
    Figure US20150270498A1-20150924-C00008
    Figure US20150270498A1-20150924-C00009
    Figure US20150270498A1-20150924-C00010
  • In Formulae 4-1 to 4-23, * and *′ may be binding sites with adjacent atoms.
  • In Formulae 2-1 and 2-2, a1 may be selected from 0, 1, 2, and 3. For example, a1 in Formulae 2-1 and 2-2 may be 0 or 1. When a1 in Formulae 2-1 and 2-2 is 0, (L1)a1- may be a single bond. When a1 in Formulae 2-1 and 2-2 is 2 or greater, a plurality of L1s may be identical to or different from each other.
  • In Formulae 1A and 1B, R1 to R22 may be each independently selected from a group represented by Formula 2-1, a group represented by Formula 2-2, a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C1-C60 alkyl group, a substituted or unsubstituted C2-C60 alkenyl group, a substituted or unsubstituted C2-C60 alkynyl group, a substituted or unsubstituted C1-C60 alkoxy group, a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C2-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, a substituted or unsubstituted C2-C10 heterocycloalkenyl group, a substituted or unsubstituted C6-C60 aryl group, a substituted or unsubstituted C6-C60 aryloxy group, a substituted or unsubstituted C6-C60 arylthio group, a substituted or unsubstituted C2-C60 heteroaryl group, a substituted or unsubstituted monovalent nonaromatic condensed polycyclic group, a substituted or unsubstituted monovalent nonaromatic condensed heteropolycyclic group (wherein the substituted monovalent nonaromatic condensed heteropolycyclic group may exclude the group of Formula 2-1 and the group of Formula 2-2), —N(Q1)(Q2), —Si(Q3)(Q4)(Q5), and —B(Q6)(Q7); and
  • at least one of R1 to R10 may be a group represented by Formula 2-1 or 2-2, and at least one of R1 to R22 may be a group represented by Formula 2-1 or 2-2.
  • In some embodiments, at least one substituent of R1 to R10 in Formula 1A, except for the groups represented by Formulae 2-1 and Formula 2-2, and at least one substituent of R1 to R22 in Formula 1B, except for the groups represented by Formulae 2-1 and Formula 2-2, may be each independently an electron transport moiety selected from a substituted or unsubstituted C2-C20 heteroaryl group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group. For example, at least one substituent of R1 to R10 in Formula 1A, except for the groups represented by Formulae 2-1 and Formula 2-2, and at least one substituent of R11 to R22 in Formula 1B, except for the groups represented by Formulae 2-1 and Formula 2-2, may be each independently selected from a substituted or unsubstituted C2-C20 heteroaryl group including at least one N as a ring-forming element, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group including at least one N as a ring-forming element. However, embodiments of the present disclosure are not limited thereto.
  • For example, at least one substituent of R1 to R10 in Formula 1A, except for the groups represented by Formulae 2-1 and Formula 2-2, and at least one substituent of R11 to R22 in Formula 1B, except for the groups represented by Formulae 2-1 and Formula 2-2, may be each independently selected from
  • a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isooxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzooxazolyl group, an isobenzooxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group, and
  • a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isooxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzooxazolyl group, an isobenzooxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group, each substituted with at least one of a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a pentalenyl group, an indeyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluorantenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenyl group, a pycenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovalenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isooxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzooxazolyl group, an isobenzooxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a thiadiazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group. However, embodiments of the present disclosure are not limited thereto.
  • In some embodiments, in Formulae 1A and 1B, R1 to R22 may be each independently selected from
  • a group represented by Formula 2-1, a group represented by Formula 2-2, a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, and a C1-C20 alkoxy group,
  • a phenyl group, a pentalenyl group, an indeyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenyl group, a picenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovalenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isooxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzooxazolyl group, an isobenzooxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a thiadiazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group,
  • a phenyl group, a pentalenyl group, an indeyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluorantenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenyl group, a pycenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovalenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isooxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzooxazolyl group, an isobenzooxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a thiadiazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexenyl group, a phenyl group, a pentalenyl group, an indeyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluorantenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenyl group, a pycenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovalenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isooxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzooxazolyl group, an isobenzooxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a thiadiazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group, and
  • Si(Q3)(Q4)(Q5), wherein Q3 to Q5 may be each independently selected from a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, and a nahthyl group; and
  • at least one of R1 to R10 may be a group represented by Formula 2-1 or Formula 2-2, and at least one of R11 to R22 may be a group represented by Formula 2-1 or Formula 2-2.
  • In some other embodiments, in Formulae 1A and 1B, R1 to R22 may be each independently selected from
  • a group represented by Formula 2-1, a group represented by Formulae 2-2, hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, and a C1-C20 alkoxy group,
  • a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group,
  • a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group, and
  • Si(Q3)(Q4)(Q5), wherein Q3 to Q5 may be each independently selected from a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, and a nahthyl group; and
  • at least one of R1 to R10 may be a group represented by Formula 2-1 or Formula 2-2, and at least one of R11 to R22 may be a group represented by Formula 2-1 or Formula 2-2.
  • In some embodiments, R1 or R2 in Formula 1A may be a group represented by Formula 2-1 or Formula 2-2.
  • In some embodiments, one of R1 to R10 in Formula 1A, and one of R11 to R22 in Formula 1B may be a group represented by Formula 2-1 or Formula 2-2. The pyrene backbone of the pyrene core represented by Formula 1A may include only one of the group of Formula 2-1 and the group of Formula 2-2 as a substituent, and the chrysene backbone of the chrysene core represented by Formula 1B may include only one of the group of Formula 2-1 and the group of Formula 2-2 as a substituent.
  • In some embodiments, R1 to R22 in Formulae 1A and 1B may be each independently selected from a group of Formula 2-1, a group of Formula 2-2, a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, Si(Q3)(Q4)(Q5) (where Q3 to Q5 may be each independently selected from a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, and a naphthyl group), and the groups of Formulae 5-1 to 5-35, wherein at least one of R1 to R10 may be a group of Formula 2-1 or a group of Formula 2-2, and at least one of R11 to R22 may be a group of Formula 2-1 or a group of Formula 2-2. However, embodiments of the present disclosure are not limited thereto:
  • Figure US20150270498A1-20150924-C00011
    Figure US20150270498A1-20150924-C00012
    Figure US20150270498A1-20150924-C00013
    Figure US20150270498A1-20150924-C00014
    Figure US20150270498A1-20150924-C00015
  • In some embodiments, R31 and R32 in Formulae 2-1 and 2-2 may be each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C10 cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C2-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.
  • For example, R31 and R32 in Formulae 2-1 and 2-2 may be each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group, but are not limited thereto.
  • In some embodiments, R31 and R32 in Formulae 2-1 and 2-2 may be each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C10 alkyl group, and a C1-C10 alkoxy group.
  • In some other embodiments, R31 and R32 in Formulae 2-1 and 2-2 may be both hydrogens.
  • In Formulae 2-1 and 2-2, b1, which indicates the number of R31s, may be an integer selected from 1 to 3. When b1 is 2 or greater, b1 number of R31s may be identical to or different from each other.
  • In Formulae 2-1 and 2-2, b2, which indicates the number of R32s, may be an integer selected from 1 to 5. When b2 is 2 or greater, b2 number of R32s may be identical to or different from each other.
  • In some embodiments, the group of Formula 2-1 may be selected from groups represented by Formulae 2-1(1), 2-1(2), and 2-1(3), and the group of Formula 2-2 may be selected from groups represented by Formulae 2-2(1) and 2-2(2). However, embodiments of the present disclosure are not limited thereto:
  • Figure US20150270498A1-20150924-C00016
  • In Formulae 2-1(1), 2-1(2), 2-1(3), 2-2(1), and 2-2(2), X1, L1, a1, R31, R32, b1, and b2 may be the same as those defined above, and thus detailed descriptions thereof will be omitted here.
  • With regard to the definition of R1 to R22 in Formulae 1A and 1B, the “substituted monovalent non-aromatic condensed heteropolycyclic group” for R1 to R22 may exclude the group of Formula 2-1 and the group of Formula 2-2.
  • In some embodiments, the condensed cyclic compound of Formula 1A may be represented by one of Formulae 1A-1 to 1A-4, and the condensed cyclic compound of Formula 1B may be represented by one of Formulae 1B-1 and 1B-2:
  • Figure US20150270498A1-20150924-C00017
    Figure US20150270498A1-20150924-C00018
  • In Formulae 1A-1 to 1A-4, and Formulae 1B-1 and 1B-2, X1, L1, a1, R6, R7, R31, R32, b1, and b2 may be the same as those defined herein.
  • In some other embodiments, the condensed cyclic compound of Formula 1A may be represented by one of Formulae 1A-1(1), 1A-1(2), 1A-2(1), 1A-2(2), 1A-3(1), 1A-3(2), 1A-3(3), 1A-4(1), and 1A-4(2), and the condensed cyclic compound of Formula 1B may be represented by one of Formulae 1B-1(1), 1B-1(2), 1B-1(3), 1B-2(1), and 1B-2(2):
  • Figure US20150270498A1-20150924-C00019
    Figure US20150270498A1-20150924-C00020
    Figure US20150270498A1-20150924-C00021
  • In Formulae 1A-1(1), 1A-1(2), 1A-2(1), 1A-2(2), 1A-3(1), 1A-3(2), 1A-3(3), 1A-4(1), 1A-4(2), 1B-1(1), 1B-1(2), 1B-1(3), 1B-2(1), and 1B(2), X1, L1, a1, R6, R7, R16, R31, R32, b1, and b2 may be the same as those defined herein.
  • For example, the condensed cyclic compound of Formula 1A or Formula 1B may be represented by one of Formulae 1A-1(1), 1A-1(2), 1A-2(1), 1A-2(2), 1A-3(1), 1A-3(2), 1A-3(3), 1A-4(1), 1A-4(2), 1B-1(1), 1B-1(2), 1B-1(3), 1B-2(1), and 1B(2), wherein, in Formulae 1A-1(1), 1A-1(2), 1A-2(1), 1A-2(2), 1A-3(1), 1A-3(2), 1A-3(3), 1A-4(1), 1A-4(2), 1B-1(1), 1B-1(2), 1B-1(3), 1B-2(1), and 1B(2),
  • L1 may be selected from groups represented by Formulae 3-1 to 3-32 (for example, groups represented by Formulae 4-1 to 4-23);
  • a1 may be 0 or 1;
  • R6, R7, and R16 may be selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, Si(Q3)(Q4)(Q5) (where Q3 to Q5 may be each independently selected from a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, and a naphthyl group), and the groups represented by Formulae 5-1 to 5-35;
  • R3 and R32 may be each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C10 alkyl group, and a C1-C10 alkoxy group; and
  • b1 and b2 may be an integer selected from 1 to 3. However, embodiments of the present disclosure are not limited thereto.
  • In some embodiments, the condensed cyclic compound of Formula 1 may be one of Compounds 1A to 133A and Compounds 1B to 92B.
  • Figure US20150270498A1-20150924-C00022
    Figure US20150270498A1-20150924-C00023
    Figure US20150270498A1-20150924-C00024
    Figure US20150270498A1-20150924-C00025
    Figure US20150270498A1-20150924-C00026
    Figure US20150270498A1-20150924-C00027
    Figure US20150270498A1-20150924-C00028
    Figure US20150270498A1-20150924-C00029
    Figure US20150270498A1-20150924-C00030
    Figure US20150270498A1-20150924-C00031
    Figure US20150270498A1-20150924-C00032
    Figure US20150270498A1-20150924-C00033
    Figure US20150270498A1-20150924-C00034
    Figure US20150270498A1-20150924-C00035
    Figure US20150270498A1-20150924-C00036
    Figure US20150270498A1-20150924-C00037
    Figure US20150270498A1-20150924-C00038
    Figure US20150270498A1-20150924-C00039
    Figure US20150270498A1-20150924-C00040
    Figure US20150270498A1-20150924-C00041
    Figure US20150270498A1-20150924-C00042
    Figure US20150270498A1-20150924-C00043
    Figure US20150270498A1-20150924-C00044
    Figure US20150270498A1-20150924-C00045
    Figure US20150270498A1-20150924-C00046
    Figure US20150270498A1-20150924-C00047
    Figure US20150270498A1-20150924-C00048
    Figure US20150270498A1-20150924-C00049
    Figure US20150270498A1-20150924-C00050
    Figure US20150270498A1-20150924-C00051
    Figure US20150270498A1-20150924-C00052
    Figure US20150270498A1-20150924-C00053
    Figure US20150270498A1-20150924-C00054
    Figure US20150270498A1-20150924-C00055
    Figure US20150270498A1-20150924-C00056
    Figure US20150270498A1-20150924-C00057
    Figure US20150270498A1-20150924-C00058
    Figure US20150270498A1-20150924-C00059
    Figure US20150270498A1-20150924-C00060
    Figure US20150270498A1-20150924-C00061
    Figure US20150270498A1-20150924-C00062
    Figure US20150270498A1-20150924-C00063
    Figure US20150270498A1-20150924-C00064
    Figure US20150270498A1-20150924-C00065
    Figure US20150270498A1-20150924-C00066
    Figure US20150270498A1-20150924-C00067
    Figure US20150270498A1-20150924-C00068
    Figure US20150270498A1-20150924-C00069
    Figure US20150270498A1-20150924-C00070
    Figure US20150270498A1-20150924-C00071
    Figure US20150270498A1-20150924-C00072
    Figure US20150270498A1-20150924-C00073
    Figure US20150270498A1-20150924-C00074
    Figure US20150270498A1-20150924-C00075
    Figure US20150270498A1-20150924-C00076
    Figure US20150270498A1-20150924-C00077
    Figure US20150270498A1-20150924-C00078
    Figure US20150270498A1-20150924-C00079
    Figure US20150270498A1-20150924-C00080
    Figure US20150270498A1-20150924-C00081
    Figure US20150270498A1-20150924-C00082
    Figure US20150270498A1-20150924-C00083
    Figure US20150270498A1-20150924-C00084
    Figure US20150270498A1-20150924-C00085
    Figure US20150270498A1-20150924-C00086
    Figure US20150270498A1-20150924-C00087
    Figure US20150270498A1-20150924-C00088
    Figure US20150270498A1-20150924-C00089
    Figure US20150270498A1-20150924-C00090
    Figure US20150270498A1-20150924-C00091
    Figure US20150270498A1-20150924-C00092
    Figure US20150270498A1-20150924-C00093
    Figure US20150270498A1-20150924-C00094
    Figure US20150270498A1-20150924-C00095
    Figure US20150270498A1-20150924-C00096
    Figure US20150270498A1-20150924-C00097
    Figure US20150270498A1-20150924-C00098
    Figure US20150270498A1-20150924-C00099
    Figure US20150270498A1-20150924-C00100
    Figure US20150270498A1-20150924-C00101
    Figure US20150270498A1-20150924-C00102
    Figure US20150270498A1-20150924-C00103
    Figure US20150270498A1-20150924-C00104
    Figure US20150270498A1-20150924-C00105
    Figure US20150270498A1-20150924-C00106
    Figure US20150270498A1-20150924-C00107
    Figure US20150270498A1-20150924-C00108
    Figure US20150270498A1-20150924-C00109
    Figure US20150270498A1-20150924-C00110
    Figure US20150270498A1-20150924-C00111
    Figure US20150270498A1-20150924-C00112
    Figure US20150270498A1-20150924-C00113
  • At least one of R1 to R10 in Formula 1A may be a group of Formula 2-1 or a group of Formula 2-2, at least one of R1 to R22 in Formula 1B may be a group of Formula 2-1 or a group of Formula 2-2. Since the groups of Formulae 2-1 and 2-2 have essentially include “—CN (a cyano group)” as a substituent, the condensed cyclic compounds represented by Formulae 1A and 1B may have improved charge transport characteristics, improved emission characteristic, and a high glass transition temperature. Accordingly, an organic light-emitting device including at least one of the condensed cyclic compounds of Formulae 1A and 1B may have enhanced heat resistance against a Joule heat generated between organic layers or between an organic layer and an electrode under high-temperature environments, during storage and/or operation, and thus may have improved lifetime characteristics.
  • Therefore, an organic light-emitting device including at least one of the condensed cyclic compounds represented by Formulae 1A and 1B above may have a low driving voltage, a high luminance, a high efficiency, and a long lifetime.
  • The at least one of the condensed cyclic compounds of Formula 1A and 1B may be synthesized using a known organic synthesis method. Methods of synthesizing the condensed cyclic compounds of Formula 1 may be understood by those of ordinary skill in the art based on the examples that will be described below.
  • The at least one of the condensed cyclic compounds of Formula 1A and 1B may be used between a pair of electrodes of the organic light-emitting device. For example, the at least one of the condensed cyclic compounds of Formula 1A and 1B may be in an electron transport region, for example, in an electron transport layer.
  • According to another embodiment of the present disclosure, an organic light-emitting device includes a first electrode, a second electrode disposed opposite to the first electrode, and an organic layer disposed between the first electrode and the second electrode and including an emission layer, wherein the organic layer includes at least one of the condensed cyclic compounds of Formula 1A and 1B described above.
  • As used herein, “(for example, the organic layer) including at least one condensed cyclic compound means that “(the organic layer) including one of the condensed cyclic compounds of Formulae 1A and 1B, or at least two different condensed cyclic compounds of Formula 1A and 1B.”
  • In some embodiments, the organic layer may include only Compound 1A as the condensed cyclic compound. In this regard, Compound 1A may be present in the electron transport layer of the organic light-emitting device. In some embodiments, the organic layer may include Compounds 1A and 2A as the condensed cyclic compounds. In this regard, Compounds 1A and 2A may be present both in the same layer (for example, in the electron transport layer) or may be present in different layers (for example, in the emission layer and the electron transport layer, respectively).
  • The organic layer may include i) a hole transport region disposed between the first electrode (anode) and the emission layer and including at least one of a hole injection layer, a hole transport layer, a buffer layer, and an electron blocking layer; and ii) an electron transport region disposed between the emission layer and the second electrode (cathode) and including at least one of a hole blocking layer, an electron transport layer, and an electron injection layer. The electron transport region may include at least one of the condensed cyclic compounds of Formulae 1A and 1B. For example, the electron transport region may include the electron transport layer, wherein the electron transport layer may include the at least one of the condensed cyclic compounds of Formulae 1A and 1B.
  • As used herein, the term “organic layer” refers to a single layer and/or a plurality of layers disposed between the first and second electrodes of the organic light-emitting device. A material in the “organic layer” is not limited to an organic material.
  • Hereinafter, a structure of an organic light-emitting device according to an embodiment of the present disclosure and a method of manufacturing the same will now be described with reference to FIG. 1.
  • FIG. 1 is a schematic sectional view of an organic light-emitting device 10 according to an embodiment of the present disclosure. Referring to FIG. 1, the organic light-emitting device 10 includes a first electrode 110, an organic layer 150, and a second electrode 190.
  • A substrate (not shown) may be disposed under the first electrode 110 or on the second electrode 190 in FIG. 1. The substrate may be a glass or transparent plastic substrate with good mechanical strength, thermal stability, transparency, surface smoothness, ease of handling, and water resistance.
  • For example, the first electrode 110 may be formed by depositing or sputtering a first electrode-forming material on the substrate 11. When the first electrode 110 is an anode, a material having a high work function may be used as the first electrode-forming material to facilitate hole injection. The first electrode 110 may be a reflective electrode, a semi-transmissive electrode, or a transmissive electrode. Transparent and conductive materials such as ITO, IZO, SnO2, and ZnO may be used to form the first electrode. The first electrode 110 as a semi-transmissive electrode or a reflective electrode may comprise at least one material selected from magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), and magnesium-silver (Mg—Ag).
  • The first electrode 110 may have a single-layer structure or a multi-layer structure including a plurality of layers. For example, the first electrode 110 may have a three-layered structure of ITO/Ag/ITO, but is not limited thereto.
  • The organic layer 150 may be disposed on the first electrode 110. The organic layer 150 may include an emission layer (EML).
  • The organic layer 150 may include a hole transport region disposed between the first electrode and the EML, and an electron transport region between the EML and the second electrode.
  • For example, the hole transport region may include at least one of a hole injection layer (HIL), a hole transport layer (HTL), a buffer layer, and an electron blocking layer (EBL). For example, the electron transport layer may include at least one of a hole blocking layer (HBL), an electron transport layer (ETL), and an electron injection layer (EIL). However, embodiments of the present disclosure are not limited thereto.
  • The hole transport region may have a single-layered structure including a single material, a single-layered structure including a plurality of materials, or a multi-layered structure including a plurality of layers including different materials.
  • In some embodiments, the electron transport region may have a single-layered structure including a plurality of materials, or a multi-layered structure of HIL/HTL, HIL/HTL/buffer layer, HIL/buffer layer, HTL/buffer layer, or HIL/HTL/EBL, wherein these layers forming a multi-layered structure are sequentially disposed on the first electrode 110 in the order stated above. However, embodiments of the present disclosure are not limited thereto.
  • When the hole transport region includes a HIL, the HIL may be formed on the first electrode 110 by using any of a variety of methods, for example, by using vacuum deposition, spin coating, casting, Langmuir-Blodgett (LB) deposition, inkjet printing, laser printing, laser induced thermal imaging (LITI), or the like.
  • When the HIL is formed using vacuum deposition, the deposition conditions may vary depending on the material that is used to form the HIL and the structure of the HIL. For example, the deposition conditions may be selected from the following conditions: a deposition temperature of about 100° C. to about 500° C., a degree of vacuum of about 10−8 to about 10−3 torr, and a deposition rate of about 0.01 to 100 Å/sec.
  • When the HIL is formed using spin coating, the coating conditions may vary depending on the material that is used to form the HIL and the structure of the HIL. For example, the coating conditions may be selected from the following conditions: a coating rate of about 2,000 rpm to about 5,000 5 pm and a heat treatment temperature of about 800° C. to about 200° C.
  • When the hole transport region includes a HTL, the HTL may be formed on the first electrode 110 or the HIL by using any of a variety of methods, for example, by using vacuum deposition, spin coating, casting, Langmuir-Blodgett (LB) deposition, inkjet printing, laser printing, laser induced thermal imaging (LITI), or the like. When the HTL is formed using vacuum deposition or spin coating, the conditions for deposition and coating may be similar to the above-described deposition and coating conditions for forming the HIL, and accordingly will not be described in detail.
  • In some embodiments, the hole transport region may include at least one of m-MTDATA, TDATA, 2-TNATA, NPB, β-NPB, TPD, Spiro-TPD, Spiro-NPB, α-NPB, TAPC, HMTPD, 4,4′,4″-tris(N-carbazolyl)triphenylamine (TCTA), polyaniline/dodecylbenzene sulfonic acid (Pani/DBSA), poly(3,4-ethylenedioxythiophene)/poly(4-styrenesulfonate)(PEDOT/PSS), polyaniline/camphor sulfonic acid (Pani/CSA), polyaniline/poly(4-styrenesulfonate) (PANI/PSS), a compound represented by Formula 201 below, and a compound represented by Formula 202 below.
  • Figure US20150270498A1-20150924-C00114
    Figure US20150270498A1-20150924-C00115
    Figure US20150270498A1-20150924-C00116
  • In Formulae 201 and 202,
  • L201 to L205 may be each independently defined as described above in conjunction with L1 in Formula 1;
  • xa1 to xa4 are each independently selected from 0, 1, 2, and 3;
  • xa5 may be selected from 1, 2, 3, 4, and 5;
  • R201 to R204 may be each independently selected from a substituted or unsubstituted C3-C10cycloalkyl group, a substituted or unsubstituted C2-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, a substituted or unsubstituted C2-C10 heterocycloalkenyl group, a substituted or unsubstituted C6-C60 aryl group, a substituted or unsubstituted C6-C60 aryloxy group, a substituted or unsubstituted C6-C60 arylthio group, a substituted or unsubstituted C2-C60 heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group.
  • For example, in Formulae 201 and 202,
  • L201 to L205 may be each independently
  • a phenylene group, a naphthylene group, a fluorenylene group, a spiro-fluorenylene group, a benzofluorene group, a dibenzofluorene group, a phenanthrenylene group, an anthracenylene group, a pyrenylene group, a chrysenylene group, a pyridinylene group, a pyrazinylene group, a pyrimidinylene group, a pyridazinylene group, a quinolinylene group, an isoquinolinylene group, a quinoxalinylene group, a quinazolinylene group, a carbazolylene group, or a triazinylene; or
  • a phenylene group, a naphthylene group, a fluorenylene group, a spiro-fluorenylene group, a benzofluorenylene group, a dibenzofluorenylene group, a phenanthrenylene group, an anthracenylene group, a pyrenylene group, a chrysenylene group, a pyridinylene group, a pyrazinylene group, a pyrimidinylene group, a pyridazinylene group, a quinolinylene group, an isoquinolinylene group, a quinoxalinylene group, a quinazolinylene group, a carbazolylene group, or a triazinylene group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group,
  • xa1 to xa4 may be each independently 0, 1, or 2;
  • xa5 may be 1, 2, or 3;
  • R201 to R204 may be each independently,
  • a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, or a triazinyl group; or
  • a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, or a triazinyl group, each substituted with at least one of a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, an azulenyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group. However, embodiments of the present disclosure are not limited thereto.
  • The compound of Formula 201 may be represented by Formula 201A:
  • Figure US20150270498A1-20150924-C00117
  • For example, the compound of Formula 201 may be represented by Formula 201A-1, but is not limited thereto:
  • Figure US20150270498A1-20150924-C00118
  • The compound of Formula 202 may be represented by Formula 202A, but is not limited thereto:
  • Figure US20150270498A1-20150924-C00119
  • In Formulae 201A, 201A-1, and 202A,
  • L201 to L203, xa1 to xa3, xa5, and R202 to R204 may be defined as described in conjunction with Formula 201;
  • R211 may be defined as described in conjunction with R203 in Formula 201;
  • R213 to R216 may be each independently a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C1-C10 cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C2-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, or a monovalent non-aromatic hetero-condensed polycyclic group.
  • In some other embodiments, in Formulae 201A, 201A-1, and 202A,
  • L201 to L203 may be each independently
  • a phenylene group, a naphthylene group, a fluorenylene group, a spiro-fluorenylene group, a benzofluorenylene group, a dibenzofluorenylene group, a phenanthrenylene group, an anthracenylene group, a pyrenylene group, a chrysenylene group, a pyridinylene group, a pyrazinylene group, a pyrimidinylene group, a pyridazinylene group, a quinolinylene group, an isoquinolinylene group, a quinoxalinylene group, a quinazolinylene group, a carbazolylene group, or a triazinylene group; or
  • a phenylene group, a naphthylene group, a fluorenylene group, a spiro-fluorenylene group, a benzofluorenylene group, a dibenzofluorenylene group, a phenanthrenylene group, an anthracenylene group, a pyrenylene group, a chrysenylene group, a pyridinylene group, a pyrazinylene group, a pyrimidinylene group, a pyridazinylene group, a quinolinylene group, an isoquinolinylene group, a quinoxalinylene group, a quinazolinylene group, a carbazolylene group, or a triazinylene group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group,
  • xa1 to xa3 may be each independently 0 or 1,
  • R203, R211, and R212 may be each independently
  • a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, or a triazinyl group; or
  • a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, or a triazinyl group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group,
  • R213 and R214 may be each independently
  • a C1-C20 alkyl group or a C1-C20 alkoxy group;
  • a C1-C20 alkyl group or a C1-C20 alkoxy group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group;
  • a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, or a triazinyl group; or
  • a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, or a triazinyl group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group,
  • R215 and R216 may be each independently
  • a hydrogen, a deuterium. —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, or a C1-C20 alkoxy group;
  • a C1-C20 alkyl group or a C1-C20 alkoxy group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group;
  • a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, or a triazinyl group; and
  • a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, or a triazinyl group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group, and
  • xa5 may be 1 or 2.
  • In Formulae 201A and 201A-1, R213 and R214 may be linked to each other to form a saturated or unsaturated ring.
  • The compound represented by Formula 201, and the compound represented by Formula 202 may be compounds HT1 to HT20 illustrated below, but are not limited thereto.
  • Figure US20150270498A1-20150924-C00120
    Figure US20150270498A1-20150924-C00121
    Figure US20150270498A1-20150924-C00122
    Figure US20150270498A1-20150924-C00123
    Figure US20150270498A1-20150924-C00124
    Figure US20150270498A1-20150924-C00125
  • A thickness of the hole transport region may be from about 100 Å to about 10000 Å, and in some embodiments, from about 100 Å to about 1000 Å. When the hole transport region includes a HIL and a HTL, a thickness of the HIL may be from about 100 Å to about 10,000 Å, and in some embodiments, from about 100 Å to about 1,000 Å, and a thickness of the HTL may be from about 50 Å to about 2,000 Å, and in some embodiments, from about 100 Å to about 1,500 Å. When the thicknesses of the hole transport region, the HIL, and the HTL are within these ranges, satisfactory hole transport characteristics may be obtained without a substantial increase in driving voltage.
  • The hole transport region may further include a charge-generating material to improve conductivity, in addition to the materials as described above. The charge-generating material may be homogeneously or inhomogeneously dispersed in the hole transport region.
  • The charge-generating material may be, for example, a p-dopant. The p-dopant may be one of quinine derivatives, metal oxides, and compounds with a cyano group, but is not limited thereto. Non-limiting examples of the p-dopant are quinone derivatives such as tetracyanoquinonedimethane (TCNQ), 2,3,5,6-tetrafluoro-tetracyano-1,4-benzoquinonedimethane (F4-TCNQ), and the like, metal oxides such as tungsten oxide, molybdenum oxide, and the like; and Compound HT-D1 below.
  • Figure US20150270498A1-20150924-C00126
  • The hole transport region may further include at least one of a buffer layer and an EBL, in addition to the HIL and HTL described above. The buffer layer may compensate for an optical resonance distance of light according to a wavelength of the light emitted from the EML, and thus may improve light-emission efficiency. A material in the buffer layer may be any material used in the hole transport region. The EBL may block migration of electrons from the electron transport region into the EML.
  • The EML may be formed on the first electrode 110 or the hole transport region by using any of a variety of methods, for example, by using vacuum deposition, spin coating, casting, Langmuir-Blodgett (LB) deposition, inkjet printing, laser printing, laser induced thermal imaging (LITI), or the like. When the EML is formed using vacuum deposition or spin coating, the deposition and coating conditions for forming the EML may be similar to the above-described deposition and coating conditions for forming the HIL, and accordingly will not be described in detail.
  • When the organic light-emitting device 10 is a full color organic light-emitting device, the EML may be patterned into a red emission layer, a green emission layer, and a blue emission layer to correspond to individual subpixels, respectively. In some embodiments, the EML may have a structure in which a red emission layer, a green emission layer and a blue emission layer are stacked upon one another, or a structure including a mixture of a red light-emitting material, a green light-emitting material, and a blue light-emitting material, and thus may emit white light.
  • The EML may include a host and a dopant.
  • For example, the host may include at least one of TPBi, TBADN, ADN (also referred to as “DNA”), CBP, CDBP, and TCP.
  • Figure US20150270498A1-20150924-C00127
    Figure US20150270498A1-20150924-C00128
  • In some embodiments, the host may include a compound represented by Formula 301.

  • Ar301-[(L301)xb1-R301]xb2  <Formula 301>
  • In Formula 301,
  • Ar301 may be
  • a naphthalene, a heptalene, a fluorene, a spiro-fluorene, a benzofluorene, a dibenzofluorene, a phenalene, a phenanthrene, an anthracene, a fluoranthene, a triphenylene, a pyrene, a chrysene, a naphthacene, a picene, a perylene, a pentaphene, or an indenoanthracene; and
  • a naphthalene, a heptalene, a fluorene, a spiro-fluorene, a benzofluorene, a dibenzofluorene, a phenalene, a phenanthrene, an anthracene, a fluoranthene, a triphenylene, a pyrene, a chrysene, a naphthacene, a picene, a perylene, a pentaphene, or an indenoanthracene, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C10 cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C2-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic hetero-condensed polycyclic group, and —Si(Q301)(Q302)(Q303) (where Q301 to Q303 may be each independently, a hydrogen, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C6-C60 aryl group, or a C2-C60 heteroaryl group),
  • L301 may be defined as described above in conjunction with L201 in Formula 201,
  • R301 may be
  • a C1-C20 alkyl group, or a C1-C20 alkoxy group;
  • a C1-C20 alkyl group, or a C1-C20 alkoxy group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group;
  • a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazole group, or a triazinyl group; or
  • a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazole group, or a triazinyl group, each substituted at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group,
  • xb1 may be selected from 0, 1, 2, and 3;
  • xb2 may be selected from 1, 2, 3, and 4.
  • For example, in Formula 301,
  • L301 may be
  • a phenylene group, a naphthylene group, a fluorenylene group, a spiro-fluorenylene group, a benzofluorenylene group, a dibenzofluorenylene group, a phenanthrenylene group, an anthracenylene group, a pyrenylene group, or a chrysenylene group; or
  • a phenylene group, a naphthylene group, a fluorenylene group, a spiro-fluorenylene group, a benzofluorenylene group, a dibenzofluorenylene group, a phenanthrenylene group, an anthracenylene group, a pyrenylene group, or a chrysenylene group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, and a chrysenyl group, and
  • R301 may be
  • a C1-C20 alkyl group, or a C1-C20 alkoxy group;
  • a C1-C20 alkyl group or a C1-C20 alkoxy group, each substituted at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, and a chrysenyl group;
  • a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, or a chrysenyl group;
  • a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, or a chrysenyl group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, and a chrysenyl group. However, embodiments of the present disclosure are not limited thereto.
  • For example, the host may include a compound represented by Formula 301A:
  • Figure US20150270498A1-20150924-C00129
  • Substituents in Formula 301A may be defined as described above in conjunction with other formulas herein.
  • The compound of Formula 301 may include at least one of Compounds H1 to 42, but is not limited thereto:
  • Figure US20150270498A1-20150924-C00130
    Figure US20150270498A1-20150924-C00131
    Figure US20150270498A1-20150924-C00132
    Figure US20150270498A1-20150924-C00133
    Figure US20150270498A1-20150924-C00134
    Figure US20150270498A1-20150924-C00135
    Figure US20150270498A1-20150924-C00136
    Figure US20150270498A1-20150924-C00137
    Figure US20150270498A1-20150924-C00138
    Figure US20150270498A1-20150924-C00139
  • In some other embodiments, the host may include at least one of Compounds H43 to H49, but is not limited thereto:
  • Figure US20150270498A1-20150924-C00140
    Figure US20150270498A1-20150924-C00141
  • The dopant may include at least one of a fluorescent dopant and a phosphorescent dopant.
  • The phosphorescent dopant may include an organometallic complex represented by Formula 401:
  • Figure US20150270498A1-20150924-C00142
  • In Formula 401,
  • M may be selected from iridium (Ir), platinum (Pt), osmium (Os), titanium (Ti), zirconium (Zr), hafnium (Hf), europium (Eu), terbium (Tb), and thulium (Tm);
  • X401 to X404 may be each independently a nitrogen or a carbon;
  • rings A401 and A402 may be each independently selected from a substituted or unsubstituted benzene, a substituted or unsubstituted naphthalene, a substituted or unsubstituted fluorene, a substituted or unsubstituted spiro-fluorene, a substituted or unsubstituted indene, a substituted or unsubstituted pyrrole, a substituted or unsubstituted thiophene, a substituted or unsubstituted furan, a substituted or unsubstituted imidazole, a substituted or unsubstituted pyrazole, a substituted or unsubstituted thiazole, a substituted or unsubstituted isothiazole, a substituted or unsubstituted oxazole, a substituted or unsubstituted isoxazole, a substituted or unsubstituted pyridine, a substituted or unsubstituted pyrazine, a substituted or unsubstituted pyrimidine, a substituted or unsubstituted pyridazine, a substituted or unsubstituted quinoline, a substituted or unsubstituted isoquinoline, a substituted or unsubstituted benzoquinoline, a substituted or unsubstituted quinoxaline, a substituted or unsubstituted quinazoline, a substituted or unsubstituted carbazole, a substituted or unsubstituted benzoimidazole, a substituted or unsubstituted benzofuran, a substituted or unsubstituted benzothiophene, a substituted or unsubstituted isobenzothiophene, a substituted or unsubstituted benzoxazole, a substituted or unsubstituted isobenzoxazole, a substituted or unsubstituted triazole, a substituted or unsubstituted oxadiazole, a substituted or unsubstituted triazine, a substituted or unsubstituted a dibenzofuran, and a substituted or unsubstituted a dibenzothiophene;
  • at least one substituent of the substituted benzene, the substituted naphthalene, the substituted fluorene, the substituted spiro-fluorene, the substituted indene, the substituted pyrrole, the substituted thiophene, the substituted furan, the substituted imidazole, the substituted pyrazole, the substituted thiazole, the substituted isothiazole, the substituted oxazole, the substituted isoxazole, the substituted pyridine, the substituted pyrazine, the substituted pyrimidine, the substituted pyridazine, the substituted quinoline, the substituted isoquinoline, the substituted benzoquinoline, the substituted quinoxaline, the substituted quinazoline, the substituted carbazole, the substituted benzoimidazole, the substituted benzofuran, the substituted benzothiophene, the substituted isobenzothiophene, the substituted benzoxazole, the substituted isobenzoxazole, the substituted triazole, the substituted oxadiazole, the substituted triazine, the substituted dibenzofuran, and the substituted dibenzothiophene may be selected from
  • a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, and C1-C60 alkoxy group;
  • a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, and a C1-C60 alkoxy group, each substituted with at least one of a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C3-C10cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxyl group, a C6-C60(arylthio group, a C2-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q401)(Q402), —Si(Q403)(Q404)(Q405), and —B(Q406)(Q407),
  • a C3-C10 cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C2-C60 heteroaryl group, and a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group,
  • a C3-C10 cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C2-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one of a deuterium. —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C10cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C2-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q411)(Q412), —Si(Q413)(Q414)(Q415), and —B(Q416)(Q417), and
  • —N(Q421)(Q422), —Si(Q423)(Q424)(Q425), and —B(Q426)(Q427);
  • L401 may be an organic ligand;
  • xc1 may be 1, 2, or 3;
  • xc2 may be 0, 1, 2, or 3.
  • For example, in Formula 401, L401 may be a monovalent, divalent, or trivalent organic ligand. For example, L401 in Formula 401 may be selected from a halogen ligand (for example, Cl or F), a diketone ligand (for example, acetylacetonate, 1,3-diphenyl-1,3-propanedionate, 2,2,6,6-tetramethyl-3,5-heptanedionate, or hexafluoroacetonate), a carboxylic acid ligand (for example, picolinate, dimethyl-3-pyrazolecarboxylate, or benzoate), a carbon monoxide ligand, an isonitrile ligand, a cyano ligand, and a phosphorous ligand (for example, phosphine or phosphite). However, embodiments of the present disclosure are not limited thereto.
  • When A401 in Formula 401 has at least two substituent groups, the at least two substituent groups of A401 may be linked to each other to form a saturated or unsaturated ring.
  • When A402 in Formula 401 has at least two substituents groups, the at least two substituent groups of A402 2 may be linked to each other to form a saturated or unsaturated ring.
  • When xc1 in Formula 401 is 2 or greater, a plurality of ligands
  • Figure US20150270498A1-20150924-C00143
  • in Formula 401 may be identical to or different from each other. When xc1 in Formula 1 is 2 or greater, A401 and A402 may be linked to A401 and A402 of another adjacent ligand, respectively, directly or via a linking group (for example, a C1-C5 alkylene group, —N(R′)— (where R′ is a C1-C10 alkyl group or a C6-C20 aryl group), or C(═O)—).
  • The fluorescent dopant may include at least one of Compounds PD1 to PD74, but is not limited thereto.
  • Figure US20150270498A1-20150924-C00144
    Figure US20150270498A1-20150924-C00145
    Figure US20150270498A1-20150924-C00146
    Figure US20150270498A1-20150924-C00147
    Figure US20150270498A1-20150924-C00148
    Figure US20150270498A1-20150924-C00149
    Figure US20150270498A1-20150924-C00150
    Figure US20150270498A1-20150924-C00151
    Figure US20150270498A1-20150924-C00152
    Figure US20150270498A1-20150924-C00153
    Figure US20150270498A1-20150924-C00154
    Figure US20150270498A1-20150924-C00155
    Figure US20150270498A1-20150924-C00156
    Figure US20150270498A1-20150924-C00157
    Figure US20150270498A1-20150924-C00158
  • For example, the phosphorescent dopant may include PtOEP:
  • Figure US20150270498A1-20150924-C00159
  • For example, the fluorescent dopant may further include at least one of DPAVBi, BDAVBi, TBPe, DCM, DCJTB, Coumarin 6, and C545T.
  • Figure US20150270498A1-20150924-C00160
  • For example, the fluorescent dopant may include a compound represented by Formula 501:
  • Figure US20150270498A1-20150924-C00161
  • In Formula 501,
  • Ar501 may be selected from
  • a naphthalene, a heptalene, a fluorenene, a spiro-fluorenene, a benzofluorenene, a dibenzofluorenene, a phenalene, a phenanthrene, an anthracene, a fluoranthene, a triphenylene, a pyrene, a chrysene, a naphthacene, a picene, a perylene, a pentaphene, and an indenoanthracene,
  • a naphthalene, a heptalene, a fluorenene, a spiro-fluorenene, a benzofluorenene, a dibenzofluorenene, a phenalene, a phenanthrene, an anthracene, a fluoranthene, a triphenylene, a pyrene, a chrysene, a naphthacene, a picene, a perylene, a pentaphene, and an indenoanthracene, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C10 cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C2-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, and —Si(Q501)(Q502)(Q503), wherein Q501 to Q503 may be each independently selected from a hydrogen, C1-C60 alkyl group, a C2-C60 alkenyl group, a C6-C60 aryl group, and a C2-C60 heteroaryl group;
  • L501 to L503 may be the same as those for L201 defined herein;
  • R501 and R502 may be each independently selected from
  • a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazoly group, a triazinyl group, a dibenzofuranyl group, and a dibenzothio group, and
  • a phenyl group, a naphthyl group, a fluorenyl group, spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, a triazinyl group, a dibenzofuranyl group, and a dibenzothio group, each substituted with at least one selected from a phenyl group, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, a triazinyl group, and a dibenzofuranyl group, and a dibenzothiophenyl group;
  • xd1 to xd3 may be each independently selected from 0, 1, 2, and 3; and
  • xb4 may be selected from 1, 2, 3, and 4.
  • For example, the fluorescent host may include at least one of Compounds FD1 to FD8:
  • Figure US20150270498A1-20150924-C00162
    Figure US20150270498A1-20150924-C00163
    Figure US20150270498A1-20150924-C00164
  • An amount of the dopant in the EML may be from about 0.01 parts to about 15 parts by weight based on 100 parts by weight of the host, but is not limited to this range.
  • The thickness of the EML may be about 100 Å to about 1000 Å, and in some embodiments, may be from about 200 Å to about 600 Å. When the thickness of the EML is within these ranges, the EML may have good light emitting ability without a substantial increase in driving voltage.
  • Next, the electron transport region may be disposed on the EML.
  • The electron transport region may include at least one of a HBL, an ETL, and an EIL. However, embodiments of the present disclosure are not limited thereto.
  • In some embodiments, the electron transport region may have a structure including an ETL/EIL, or a HBL/ETL/EIL, wherein the layers forming a structure of the electron transport region may be sequentially stacked on the EML in the order stated above. However, embodiments of the present disclosure are not limited thereto:
  • In some embodiments, the organic layer 150 of the organic light-emitting device 10 may include the electron transport region between the EML and the second electrode 190, and at least one of the condensed cyclic compounds of Formulae 1A and 1B may be in the electron transport region.
  • The electron transport region may include a HBL. When the EML includes a phosphorescent dopant, the HBL may prevent diffusion of triplet exitons or holes into the ETL from the EML.
  • When the electron transport region includes a HBL, the HBL may be formed on the EML by using any of a variety of methods, for example, by using vacuum deposition, spin coating, casting, Langmuir-Blodgett (LB) deposition, inkjet printing, laser printing, laser induced thermal imaging (LITI), or the like. When the HBL is formed using vacuum deposition or spin coating, the deposition and coating conditions for forming the HBL may be similar to the above-described deposition and coating conditions for forming the HIL, and accordingly will not be described in detail.
  • For example, the HBL may include at least one of BCP below and Bphen below. However, embodiments of the present disclosure are not limited thereto.
  • Figure US20150270498A1-20150924-C00165
  • A thickness of the HBL may be from about 20 Å to about 1,000 Å, and in some embodiments, from about 30 Å to about 300 Å. When the thickness of the HBL is within these ranges, the HBL may have improved hole blocking ability without a substantial increase in driving voltage.
  • The electron transport region may include an ETL. The ETL may be formed on the EML or the HBL by using any of a variety of methods, for example, by using vacuum deposition, spin coating, casting, Langmuir-Blodgett (LB) deposition, inkjet printing, laser printing, laser induced thermal imaging (LITI), or the like. When the ETL is formed using vacuum deposition or spin coating, the deposition and coating conditions for forming the ETL may be similar to the above-described deposition and coating conditions for forming the HIL, and accordingly will not be described in detail.
  • In some embodiments, the organic layer 150 of the organic light-emitting device may include an electron transport region between the EML and the second electrode 190, wherein the electron transport region may include an ETL, and the ETL may include at least one of the condensed cyclic compounds of Formulae 1A and 1B.
  • The ETL may further include at least one of BCP, Bphen Alq3, Balq, TAZ, and NTAZ, in addition to the at least one of the condensed cyclic compounds of Formulae 1A and 1B.
  • Figure US20150270498A1-20150924-C00166
  • A thickness of the ETL may be from about 100 Å to about 1,000 Å, and in some embodiments, from about 150 Å to about 500 Å. When the thickness of the ETL is within these ranges, the ETL may have satisfactory electron transporting ability without a substantial increase in driving voltage.
  • In some embodiments the ETL may further include a metal-containing material, in addition to the above-described materials.
  • The metal-containing material may include a lithium (Li) complex. Non-limiting examples of the Li complex are compound ET-D1 below (lithium quinolate (LiQ)), or compound ET-D2.
  • Figure US20150270498A1-20150924-C00167
  • The electron transport region may include an EIL that may facilitate injection of electrons from the second electrode 190.
  • The EIL may be formed on the ETL by using any of a variety of methods, for example, by using vacuum deposition, spin coating, casting, Langmuir-Blodgett (LB) deposition, inkjet printing, laser printing, laser induced thermal imaging (LITI), or the like. When the EIL is formed using vacuum deposition or spin coating, the deposition and coating conditions for forming the EIL may be similar to the above-described deposition and coating conditions for forming the HIL, and accordingly will not be described in detail.
  • The EIL may include at least one selected from LiF, NaCl, CsF, Li2O, BaO, and LiQ.
  • A thickness of the EIL may be from about 1 Å to about 100 Å, and in some embodiments, from about 3 Å to about 90 Å. When the thickness of the EIL is within these ranges, the EIL may have satisfactory electron injection ability without a substantial increase in driving voltage.
  • The second electrode 190 may be disposed on the organic layer 150, as described above. The second electrode 190 may be a cathode as an electron injecting electrode. A material for forming the second electrode 190 may be a metal, an alloy, an electrically conductive compound, which have a low-work function, or a mixture thereof. Non-limiting examples of materials for forming the second electrode 190 are lithium (Li), magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), and magnesium-silver (Mg—Ag). In some embodiments, a material for forming the second electrode 190 may be ITO or IZO. The second electrode 190 may be a reflective electrode, a semi-transmissive electrode, or a transmissive electrode.
  • Although the organic light-emitting device of FIG. 1 is described above, embodiments of the present disclosure are not limited thereto.
  • As used herein, a C1-C60 alkyl group refers to a linear or branched aliphatic hydrocarbon monovalent group having 1 to 60 carbon atoms. Non-limiting examples of the C1-C60 alkyl group a methyl group, a ethyl group, a propyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an iso-amyl group, and a hexyl group. A C1-C60 alkylene group refers to a divalent group having the same structure as the C1-C60 alkyl.
  • As used herein, a C1-C60 alkoxy group refers to a monovalent group represented by —OA101 (where A101 is a C1-C60 alkyl group as described above. Non-limiting examples of the C1-C60 alkoxy group are a methoxy group, an ethoxy group, and an isopropyloxy group.
  • As used herein, a C2-C60 alkenyl group refers to a hydrocarbon group including at least one carbon double bond in the middle or terminal of the C2-C60 alkyl group. Non-limiting examples of the C2-C60 alkenyl group are an ethenyl group, a prophenyl group, and a butenyl group. A C2-C60 alkylene group refers to a divalent group having the same structure as the C2-C60 alkenyl group.
  • As used herein, a C2-C60 alkynyl group refers to a hydrocarbon group including at least one carbon triple bond in the middle or terminal of the C2-C60 alkyl group.
  • Non-limiting examples of the C2-C60 alkynyl group are an ethynyl group and a propynyl group. A C2-C60 alkynylene group used herein refers to a divalent group having the same structure as the C2-C60 alkynyl group.
  • As used herein, a C3-C10 cycloalkyl group refers to a monovalent, monocyclic hydrocarbon group having 3 to 10 carbon atoms. Non-limiting examples of the C3-C10 cycloalkyl group are a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a cycloheptyl group. A C3-C10cycloalkylene group refers to a divalent group having the same structure as the C3-C10 cycloalkyl group.
  • As used herein, a C2-C10 heterocycloalkyl group refers to a monovalent monocyclic group having 2 to 10 carbon atoms in which at least one hetero atom selected from N, O, P, and S is included as a ring-forming atom. Non-limiting examples of the C2-C10 heterocycloalkyl group are a tetrahydrofuranyl group and a tetrahydrothiophenyl group. A C2-C10 heterocycloalkylene group refers to a divalent group having the same structure as the C2-C10 heterocycloalkyl group.
  • As used herein, a C3-C10 cycloalkenyl group refers to a monovalent monocyclic group having 3 to 10 carbon atoms that includes at least one double bond in the ring but does not have aromacity. Non-limiting examples of the C3-C10 cycloalkenyl group are a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group. A C3-C10 cycloalkenylene group refers to a divalent group having the same structure as the C3-C10 cycloalkenyl group.
  • As used herein, a C2-C10 heterocycloalkenyl group used herein refers to a monovalent monocyclic group having 2 to 10 carbon atoms that includes at least one double bond in the ring and in which at least one hetero atom selected from N, O, P, and S is included as a ring-forming atom. Non-limiting examples of the C2-C10 heterocycloalkenyl group are a 2,3-hydrofuranyl group and a 2,3-hydrothiophenyl group. A C2-C10 heterocycloalkenylene group used herein refers to a divalent group having the same structure as the C3-C10 heterocycloalkenyl group.
  • As used herein, a C6-C60 aryl group refers to a monovalent, aromatic carbocyclic aromatic group having 6 to 60 carbon atoms, and a C6-C60 arylene group refers to a divalent, aromatic carbocyclic group having 6 to 60 carbon atoms. Non-limiting examples of the C6-C60 aryl group are a phenyl group, a naphthyl group, an anthracenyl group, a phenanthrenyl group, a pyrenyl group, and a chrysenyl group. When the C6-C60 aryl group and the C6-C60 arylene group include at least two rings, the rings may be fused to each other.
  • As used herein, a C2-C60 heteroaryl group refers to a monovalent, aromatic carbocyclic aromatic group having 2 to 60 carbon atoms in which at least one hetero atom selected from N, O, P, and S is included as a ring-forming atom, and 2 to 60 carbon atoms. A C2-C60 heteroarylene group refers to a divalent, aromatic carbocyclic group having 2 to 60 carbon atoms in which at least one hetero atom selected from N, O, P, and S is included as a ring-forming atom. Non-limiting examples of the C2-C60 heteroaryl group are a pyridinyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, and an isoquinolinyl group. When the C2-C60 heteroaryl and the C2-C60 heteroarylene include at least two rings, the rings may be fused to each other.
  • As used herein, a C6-C60 aryloxy group indicates —OA102 (where A102 is a C6-C60 aryl group as described above), and a C6-C60 arylthio group indicates —SA103 (where A103 is a C6-C60 aryl group as described above).
  • As used herein, a monovalent non-aromatic condensed polycyclic group refers to a monovalent group having at least two rings condensed to each other, in which only carbon atoms (for example, 8 to 60 carbon atoms) are exclusively included as ring-forming atoms and the entire molecule has non-aromacity. A non-limiting example of the monovalent non-aromatic condensed polycyclic group is a fluorenyl group. A divalent non-aromatic condensed polycyclic group refers to a divalent group having the same structure as the monovalent non-aromatic condensed polycyclic group.
  • As used herein, a monovalent non-aromatic condensed heteropolycyclic group refers to a monovalent group having at least two rings condensed to each other, in which carbon atoms (for example, 2 to 60 carbon atoms) and a hetero atom selected from N, O. P, and S are as ring-forming atoms and the entire molecule has non-aromacity. A non-limiting example of the monovalent non-aromatic condensed heteropolycyclic group is a carbazolyl group. A divalent non-aromatic condensed heteropolycyclic group refers to a divalent group having the same structure as the monovalent non-aromatic condensed heteropolycyclic group.
  • As used herein, at least one substituent of the substituted C3-C10 cycloalkylene group, the substituted C2-C10 heterocycloalkylene group, the substituted C3-C10 cycloalkenylene group, the substituted C2-C10 heterocycloalkenylene group, the substituted C6-C60 arylene group, the substituted C2-C60 heteroarylene group, the substituted divalent non-aromatic condensed cyclic group, the substituted divalent non-aromatic hetero-condensed cyclic group, the substituted C1-C60 alkyl group, the substituted C2-C60 alkenyl group, the substituted C2-C60 alkynyl group, the substituted C1-C60 alkoxy group, the substituted C3-C10 cycloalkyl group, the substituted C2-C10 heterocycloalkyl group, the substituted C3-C10 cycloalkenyl group, the substituted C2-C10 heterocycloalkenyl group, the substituted C6-C60 aryl group, the substituted C6-C60 aryloxy group, the substituted C6-C60 arylthio group, the substituted C2-C60 heteroaryl group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic hetero-condensed polycyclic group, may be selected from
  • a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, and a C1-C60 alkoxy group,
  • a C1-C60 alkyl group, a C2-C60(alkenyl group, a C2-C60 alkynyl group, and C1-C60 alkoxy group, each substituted with at least one of a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C3-C10 cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C6 aryloxyl group, a C6-C60 arylthio group, a C2-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q11)(Q12), —Si(Q13)(Q14)(Q15), and —B(Q16)(Q17),
  • a C3-C10 cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C2-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group,
  • a C3-C10 cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C2-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one of a deuterium. —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C10 cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C2-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q21)(Q22), —Si(Q23)(Q24)(Q25), and —B(Q26)(Q27), and
  • —N(Q31)(Q32), —Si(Q33)(Q34)(Q35), and —B(Q36)(Q37),
  • wherein Q1 to Q7, Q11 to Q17, Q21 to Q27, and Q31 to Q37 may be each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C10 cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C100 cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C2-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.
  • For example, at least one substituent of the substituted C3-C10 cycloalkylene group, the substituted C2-C10 heterocycloalkylene group, the substituted C3-C10 cycloalkenylene group, the substituted C2-C10 heterocycloalkenylene group, the substituted C6-C60 heteroarylene group, the substituted C2-C60 heteroarylene group, the substituted divalent non-aromatic condensed polycyclic group, the substituted divalent non-aromatic condensed heteropolycyclic group, the substituted C1-C60 alkyl group, the substituted C2-C60 alkenyl group, the substituted C2-C60 alkynyl group, the substituted C1-C60 alkoxy group, the substituted C3-C10 cycloalkyl group, the substituted C2-C10 heterocycloalkyl group, the substituted C3-C10 cycloalkenyl group, the substituted C2-C10 heterocycloalkenyl group, the substituted C6-C60 aryl group, the substituted C6-C60 aryloxy group, the substituted C6-C60 arylthio group, the substituted C2-C60 heteroaryl group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group may be selected from
  • a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, and a C1-C60 alkoxy group,
  • a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, and a C1-C60 alkoxy group, each substituted with at least one of a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexcenyl group, a phenyl group, a pentalenyl group, an indenyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenyl group, a picenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovarenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an sobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a thiadiazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, —N(Q11)(Q12), —Si(Q13)(Q14)(Q15), and —B(Q16)(Q17),
  • a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexcenyl group, a phenyl group, a pentalenyl group, an indenyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenyl group, a picenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovarenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an sobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a thiadiazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group,
  • a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexcenyl group, a phenyl group, a pentalenyl group, an indenyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenyl group, a picenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovarenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an sobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a thiadiazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group, each substituted with at least one of a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexcenyl group, a phenyl group, a pentalenyl group, an indenyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenyl group, a picenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovarenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an sobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a thiadiazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, —N(Q21)(Q22), —Si(Q23)(Q24)(Q25), and —B(Q26)(Q27), and
  • —N(Q31)(Q32), —Si(Q33)(Q34)(Q35), and —B(Q36)(Q37),
  • wherein Q1 to Q7, Q11 to Q17, Q21 to Q27, and Q31 to Q37 may be each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexcenyl group, a phenyl group, a pentalenyl group, an indenyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenyl group, a picenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovarenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an sobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a thiadiazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group.
  • The acronym “Ph” used herein refers to phenyl, the acronym “Me” used herein refers to methyl, the acronym “Et” used herein refers to ethyl, and the acronym “ter-Bu” or “But” used herein refers to tert-butyl.
  • One or more embodiments of the present disclosure, which include condensed cyclic compounds, and organic light-emitting devices including the same, will now be described in detail with reference to the following examples. However, these examples are only for illustrative purposes and are not intended to limit the scope of the one or more embodiments of the present disclosure. In the following synthesis example, the expression that “‘B’ instead of ‘A’ was used” means that the amounts of ‘B’ and ‘A’ were the same in equivalent amounts.
  • EXAMPLES Synthesis Example 1 Synthesis of Compound 1A
  • Figure US20150270498A1-20150924-C00168
  • Synthesis of Intermediate I-1
  • 3.17 g (10 mmol) of 2-bromo-4-chloro-1-iodobenzene, 1.92 g (11 mmol) of 5-methoxy-1-naphthol, 0.112 g (0.5 mmol) of palladium acetate, 0.651 g (2.0 mmol) of triphenylphosphine, and 13 g (40 mmol) of cesium carbonate were dissolved in 60 mL of dimethylformamide (DMF), and then stirred at about 140° C. for about 24 hours. The resulting mixture was cooled down to room temperature, and 60 mL of water was added thereto, followed by extraction three times with ethylether. An organic layer was collected and was dried using magnesium sulfate to evaporate the solvent. The residue was separated and purified using silica gel column chromatography to obtain 1.70 g of Intermediate I-1 (Yield: 60%). This compound was identified using liquid chromatography-mass spectroscopy (LC-MS).
  • C17H11ClO2: M+ 282.0
  • Synthesis of Intermediate I-2
  • 1.70 g (4.2 mmol) of Intermediate I-1, 19 mg (0.084 mmol) of palladium acetate, 60 mg (0.13 mmol) of Xphos (dicyclohexyl(2′,4′,6′-triisopropyl-2-biphenylyl)phosphine), 0.44 g (1.05 mmol) of K4[Fe(CN)6].3 H2O, and 0.58 g (4.2 mmol) of potassium carbonate were dissolved in 20 mL of a mixture of H2O and 1,4-dioxane (1:1 by volume), and then stirred at about 120° C. for about 10 hours. The resulting mixture was cooled down to room temperature, followed by extraction three times with 30 mL of water and 30 mL of diethyl ether. An organic layer was collected and was dried using magnesium sulfate to evaporate the solvent. The residue was separated and purified using silica gel column chromatography to obtain 0.99 g of Intermediate I-2 (Yield: 86%). This compound was identified using LC-MS.
  • C18H11NO2: M+ 273.1
  • Synthesis of Intermediate I-3
  • 0.99 g (3.6 mmol) of Intermediate I-2 was dissolved in 20 mL of methylene chloride (MC), and 0.51 mL (5.4 mmol) of BBr3 was slowly dropwise added thereto at about −78° C. The temperature of the resulting mixture was raised to room temperature and stirred at room temperature for about 24 hours. After termination of the reaction, 10 mL of MeOH and 20 mL of H2O were added thereto, followed by extraction three times with 20 mL of MC. An organic layer was collected and was dried using magnesium sulfate to evaporate the solvent. The residue was separated and purified using silica gel column chromatography to obtain 0.87 g of Intermediate I-3 (Yield: 93%). This compound was identified using LC-MS.
  • C17H9NO2: M+ 259.1
  • Synthesis of Intermediate I-4
  • 0.87 g (3.3 mmol) of Intermediate I-3 was dissolved in 10 mL of toluene and 10 mL of a 30% potassium phosphate mixture, and 1.09 g (3.9 mmol) of trifluoromethane sulfonic anhydride was slowly dropwise added thereto at about 0° C. The reaction temperature was raised to room temperature, and the resulting mixture was stirred for about 3 hours. 20 mL of water was added thereto, followed by extraction three times with 20 mL of ethylether. An organic layer was collected and was dried using magnesium sulfate to evaporate the solvent. The residue was separated and purified using silica gel column chromatography to obtain 1.06 g of Intermediate I-4 (Yield: 82%). This compound was identified using LC-MS.
  • C18H8F3NO4S: M+ 391.0
  • Synthesis of Compound 1A
  • 1.06 g (2.71 mmol) of Intermediate I-4, 0.67 g (2.71 mmol) of pyrene boronic acid, 0.17 g (0.14 mmol) of Pd(PPh3)4, and 1.12 g (8.13 mmol) of K2CO3 were dissolved in 40 mL of a mixed solution of THF and H2O (2:1 by volume), and then stirred at about 80° C. for about 12 hours. The resulting mixture was cooled down to room temperature, followed by extraction three times with 30 mL of water and 30 mL of ethylacetate. An organic layer was collected and was dried using magnesium sulfate to evaporate the solvent. The residue was separated and purified using silica gel column chromatography to obtain 0.99 g of Compound 1A (Yield: 83%). This compound was identified using mass spectroscopy/fast atom bombardment (MS/FAB) and 1H NMR.
  • C33H17NO cal. 443.13. found 443.14.
  • Synthesis Example 2 Synthesis of Compound 3A
  • Figure US20150270498A1-20150924-C00169
  • Synthesis of Intermediate I-5
  • 5.40 g (15 mmol) of 1,6-dibromopyrene, 1.90 g (10 mmol) of 2-pyridine boronic acid, 0.58 g (0.5 mmol) of tetrakis(triphenylphosphine)palladium (Pd(PPh3)4), and 4.15 g (30 mmol) of K2CO3 were dissolved in 60 mL of a mixed solution of THF and H2O (2:1 by volume), and then stirred at about 70° C. for about 5 hours. The resulting mixture was cooled down to room temperature, followed by extraction three times with 50 mL of water and 50 mL of ethylether. An organic layer was collected and was dried using magnesium sulfate to evaporate the solvent. The residue was separated and purified using silica gel column chromatography to obtain 2.26 g of Intermediate I-5 (Yield: 63%). This compound was identified using LC-MS.
  • C21H12BrN: M+ 357.0
  • Synthesis of Intermediate I-6
  • 2.26 g (6.30 mmol) of Intermediate I-5 was dissolved in 50 mL of THF, and 3.0 mL (6.94 mmol, 2.5M in hexane) of n-BuLi was slowly dropwise added thereto, and stirred at the same temperature for about 1 hour. Then, 1.7 mL (8.23 mmol) of 2-isoproxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was dropwise added thereto and stirred at room temperature for about 24 hours. After termination of the reaction, 40 mL of water was added thereto, followed by extraction three times with 40 mL of diethyl ether. An organic layer was collected and was dried using magnesium sulfate to evaporate the solvent. The residue was separated and purified using silica gel column chromatography to obtain 1.97 g of Intermediate I-6 (Yield: 77%). This compound was identified using LC-MS.
  • C27H24BNO2: M+ 405.2
  • Synthesis of Compound 3A
  • 1.97 g (4.86 mmol) of Intermediate I-6, 1.90 g (4.86 mmol) of Intermediate I-4, 0.28 g (0.24 mmol) of Pd(PPh3)4, and 2.01 g (14.6 mmol) of K2CO3 were dissolved in 50 mL of a mixed solution of THF and H2O (2:1 by volume), and then stirred at about 80° C. for about 12 hours. The resulting mixture was cooled down to room temperature, followed by extraction three times with 40 mL of water and 40 mL of ethylacetate. An organic layer was collected and was dried using magnesium sulfate to evaporate the solvent. The residue was separated and purified using silica gel column chromatography to obtain 1.90 g of Compound 3A (Yield: 75%). This compound was identified using mass spectroscopy/fast atom bombardment (MS/FAB) and 1H NMR.
  • C38H20N2O cal. 520.16. found 520.15.
  • Figure US20150270498A1-20150924-C00170
  • Synthesis Example 3 Synthesis of Compound 16A Synthesis of Intermediate I-7
  • 3.17 g (10 mmol) of 2-bromo-4-chloro-1-iodobenzene, 1.92 g (11 mmol) of 4-methoxy-1-naphthol, 0.112 g (0.5 mmol) of palladium acetate, 0.651 g (2.0 mmol) of triphenylphosphine, and 13 g (40 mmol) of cesium carbonate were dissolved in 60 mL of dimethylformamide (DMF), and then stirred at about 140° C. for about 24 hours. The resulting mixture was cooled down to room temperature, and 60 mL of water was added thereto, followed by extraction three times with ethylether. An organic layer was collected and was dried using magnesium sulfate to evaporate the solvent. The residue was separated and purified using silica gel column chromatography to obtain 1.64 g of Intermediate I-7 (Yield: 58%). This compound was identified using LC-MS.
  • C17H11ClO2: M+ 282.0
  • Synthesis of Intermediate I-8
  • 1.64 g (5.8 mmol) of Intermediate I-7 was dissolved in 60 mL of MC, and 0.82 mL (8.7 mmol) of BBr3 was slowly dropwise added thereto at about −78° C. The reaction temperature was raised to room temperature, and the resulting mixture was stirred at room temperature for about 24 hours. After termination of the reaction, 15 mL of MeOH and 30 mL of H2O were added thereto, followed by extraction three times with 30 mL of MC. An organic layer was collected and was dried using magnesium sulfate to evaporate the solvent. The residue was separated and purified using silica gel column chromatography to obtain 1.43 g of Intermediate I-8 (Yield: 92%). This compound was identified using LC-MS.
  • C16H9ClO2: M+ 268.0
  • Synthesis of Intermediate I-9
  • 1.43 g (5.3 mmol) of Intermediate I-8 was dissolved in 20 mL of toluene and 20 mL of a 30% potassium phosphate mixture, and 1.79 g (6.4 mmol) of trifluoromethane sulfonic anhydride was slowly dropwise added thereto at about 0° C. The reaction temperature was raised to room temperature, and the resulting mixture was stirred for about 3 hours. 30 mL of water was added thereto, followed by extraction three times with 30 mL of ethylether. An organic layer was collected and was dried using magnesium sulfate to evaporate the solvent. The residue was separated and purified using silica gel column chromatography to obtain 1.70 g of Intermediate I-9 (Yield: 80%). This compound was identified using LC-MS.
  • C17H8ClF3O4S: M+ 400.0
  • Synthesis of Intermediate I-10
  • 1.70 g (4.2 mmol) of Intermediate I-9, 4.7 mg (0.021 mmol) of palladium acetate, 0.39 g (0.92 mmol) of K4[Fe(CN)6].3 H2O, and 0.58 g (4.2 mmol) of potassium carbonate were dissolved in 20 mL of a mixed solution of H2O and 1,4-dioxane (1:1 by volume), and then stirred at about 140° C. for about 10 hours. The resulting mixture was cooled down to room temperature, followed by extraction three times with 30 mL of water and 30 mL of diethyl ether. An organic layer was collected and was dried using magnesium sulfate to evaporate the solvent. The residue was separated and purified using silica gel column chromatography to obtain 0.96 g of Intermediate I-10 (Yield: 82%). This compound was identified using LC-MS.
  • C17H8ClNO: M+ 277.0
  • Synthesis of Intermediate I-11
  • Intermediate I-11 (2.26 g, Yield: 79%) was obtained in the same manner as the synthesis of Intermediate I-5, except that 2-naphthylboronic acid, instead of 2-pyridine boronic acid, was used to synthesize Intermediate I-5 of Synthesis Example 2. This compound was identified using LC-MS.
  • C32H27BO2: M+ 454.2
  • Synthesis of Compound 16A
  • 0.96 g (3.4 mmol) of Intermediate I-10, 1.54 g (3.4 mmol) of Intermediate I-11, 0.046 g (0.05 mmol) of Pd2(dba)3, 0.02 g (0.1 mmol) of PtBu3, and 1.66 g (5.1 mmol) of cesium carbonate were dissolved in 30 mL of a 1,4-dioxane solution, and then stirred at about 90° C. for about 20 hours. The resulting mixture was cooled down to room temperature, and 40 mL of water was added thereto, followed by extraction three times with ethylether. An organic layer was collected and was dried using magnesium sulfate to evaporate the solvent. The residue was separated and purified using silica gel column chromatography to obtain 1.41 g of Compound 16A (Yield: 73%). This compound was identified using MS/FAB.
  • C43H23NO: calc. 569.18. found 569.20.
  • Synthesis Example 4 Synthesis of Compound 24A
  • Figure US20150270498A1-20150924-C00171
  • Synthesis of Intermediate I-12
  • Intermediate I-9 (0.99 g, Yield: 86%) was obtained in the same manner as in the synthesis of Intermediate I-2 of Synthesis Example 1, except that Intermediate I-7 instead of Intermediate I-1 was used. This compound was identified using LC-MS.
  • C18H11NO2: M+ 273.1
  • Synthesis of Intermediate I-13
  • Intermediate I-13 (0.87 g, Yield: 93%) was obtained in the same manner as in the synthesis of Intermediate I-3 of Synthesis Example 1, except that intermediate I-12 instead of Intermediate I-2 was used. This compound was identified using LC-MS.
  • C17H9NO2: M+ 259.1
  • Synthesis of Intermediate I-14
  • Intermediate I-14 (1.06 g, Yield: 82%) was obtained in the same manner as in the synthesis of Intermediate I-4 of Synthesis Example 1, except that intermediate I-13 instead of Intermediate I-3 was used. This compound was identified using LC-MS.
  • C18H8F3NO4S: M+ 391.0
  • Synthesis of Compound 24A
  • Compound 24A (1.20 g, Yield: 85%) was obtained in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-14 and Intermediate I-15, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used. This compound was identified using MS/FAB and 1H NMR.
  • C39H21NO cal. 519.16. found 519.17.
  • Synthesis Example 5 Synthesis of Compound 72A
  • Figure US20150270498A1-20150924-C00172
  • Synthesis of Intermediate I-16
  • Intermediate I-16 (2.39 g, Yield: 67%) was obtained in the same manner as the synthesis of Intermediate I-5 of Synthesis Example 2, except that 2,7-dibromopyrene and phenyl boronic acid, instead of 1,6-dibromopyrene and 2-pyridine boronic acid, respectively, were used. This compound was identified using LC-MS.
  • C22H13Br: M+ 356.0
  • Synthesis of Intermediate I-17
  • Intermediate I-17 (2.11 g, Yield: 78%) was obtained in the same manner as in the synthesis of Intermediate I-6 of Synthesis Example 2, except that intermediate I-16 instead of Intermediate I-5 was used. This compound was identified using LC-MS.
  • C28H25BO2: M+ 404.2
  • Synthesis of Compound 72A
  • Compound 72A (2.14 g, Yield: 79%) was obtained in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-17, instead of 1-pyrene boronic acid, was used. This compound was identified using MS/FAB and 1H NMR.
  • C39H21NO cal. 519.16. found 519.15.
  • Synthesis Example 6 Synthesis of Compound 20A
  • Compound 20A (1.20 g, Yield: 85%) was obtained in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-20 and Intermediate I-20A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used. The synthesis of Intermediate I-20 is follows.
  • Figure US20150270498A1-20150924-C00173
  • Synthesis of Intermediate I-18
  • Intermediate I-18 (0.87 g, Yield: 93%) was obtained in the same manner as in the synthesis of Intermediate I-8 of Synthesis Example 3, except that intermediate I-1 instead of Intermediate I-7 was used to. This compound was identified using LC-MS.
  • C16H9ClO2: M+ 268.0
  • Synthesis of Intermediate I-19
  • Intermediate I-19 (1.06 g, Yield: 82%) was obtained in the same manner as in the synthesis of Intermediate I-9 of Synthesis Example 3, except that intermediate I-18 instead of Intermediate I-8 was used. This compound was identified using LC-MS.
  • C17H8ClF3O4S: M+ 400.0
  • Synthesis of Intermediate I-20
  • Intermediate I-20 (1.06 g, Yield: 82%) was obtained in the same manner as in the synthesis of Intermediate I-10 of Synthesis Example 3, except that intermediate I-9 instead of Intermediate I-19 was used to synthesize Intermediate I-10 of Synthesis Example 3. This compound was identified using LC-MS.
  • C17H8ClNO: M+ 277.0
  • Synthesis Example 7 Synthesis of Compound 32A
  • Compound 32A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-32A instead of 1-pyrene boronic acid was used.
  • Synthesis Example 8 Synthesis of Compound 39A
  • Compound 39A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-29 and Intermediate I-39A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used. Intermediate I-29 was synthesized in the same manner as in the synthesis of Intermediate I-7, Intermediate I-8, Intermediate I-9, and Intermediate I-10 of Synthesis Example 2, except that 2-bromo-5-chloro-1-iodobenzene, instead of 2-bromo-4-chloro-1-iodobenzene, was used.
  • Synthesis Example 9 Synthesis of Compound 46A
  • Compound 46A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-20 and Intermediate I-46A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Synthesis Example 10 Synthesis of Compound 51A
  • Compound 51A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-13 and Intermediate I-15A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Synthesis Example 11 Synthesis of Compound 55A
  • Compound 55A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-55A instead of 1-pyrene boronic acid was used.
  • Synthesis Example 12 Synthesis of Compound 62A
  • Compound 62A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-10 and Intermediate I-62A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Synthesis Example 13 Synthesis of Compound 66A
  • Compound 66A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-10 and Intermediate I-66A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Synthesis Example 14 Synthesis of Compound 76A
  • Compound 76A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-76A instead of 1-pyrene boronic acid was used.
  • Synthesis Example 15 Synthesis of Compound 81A
  • Compound 81A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-13 and Intermediate I-81A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Synthesis Example 16 Synthesis of Compound 85A
  • Compound 85A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-29 and Intermediate I-85A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Synthesis Example 17 Synthesis of Compound 94A
  • Compound 94A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-10 and Intermediate I-94A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Synthesis Example 18 Synthesis of Compound 109A
  • Compound 109A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-20 and Intermediate I-109A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Synthesis Example 19 Synthesis of Compound 13A
  • Compound 113A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-20 and Intermediate I-113A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Synthesis Example 20 Synthesis of Compound 119A
  • Compound 119A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-119A instead of 1-pyrene boronic acid was used.
  • Synthesis Example 21 Synthesis of Compound 123A
  • Compound 112A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-20 and Intermediate I-122A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Synthesis Example 22 Synthesis of Compound 128A
  • Compound 128A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-20 and Intermediate I-128A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Synthesis Example 23 Synthesis of Compound 131A
  • Compound 131A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-29 and Intermediate I-119A, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used to synthesize Compound 1A of Synthesis Example 1.
  • Synthesis Example 24 Synthesis of Compound 3B
  • Figure US20150270498A1-20150924-C00174
  • Synthesis of Intermediate I-21
  • Intermediate I-21 (2.57 g, Yield: 67%) was obtained in the same manner as the synthesis of Intermediate I-5 of Synthesis Example 2, except that 6,12-dibromochrysene and 3-pyridine boronic acid, instead of 1,6-dibromopyrene and 2-pyridine boronic acid, respectively, were used. This compound was identified using LC-MS.
  • C23H14BrN: M+ 383.0
  • Synthesis of Intermediate I-22
  • Intermediate I-22 (2.08 g, Yield: 72%) was obtained in the same manner as in the synthesis of Intermediate I-6 of Synthesis Example 2, except that intermediate I-21 instead of Intermediate I-5 was used. This compound was identified using LC-MS.
  • C29H26BNO2: M+ 431.2
  • Synthesis of Compound 3B
  • Compound 3B (1.60 g, Yield: 77%) was obtained in the same manner as in the synthesis of Compound 16An of Synthesis Example 3, except that Intermediate I-20 and Intermediate I-22, instead of Intermediate I-10 and Intermediate I-11, respectively, were used. This compound was identified using MS/FAB and 1H NMR.
  • C40H22N2O cal. 546.17. found 546.16.
  • Synthesis Example 25 Synthesis of Compound 13B
  • Figure US20150270498A1-20150924-C00175
  • Synthesis of Intermediate I-23
  • Intermediate I-23 (2.64 g, Yield: 69%) was obtained in the same manner as in the synthesis of Intermediate I-21 of Synthesis Example 24, except that phenyl boronic acid instead of 3-pyridine boronic acid was used. This compound was identified using LC-MS.
  • C24H15Br: M+ 382.0
  • Synthesis of Intermediate I-24
  • Intermediate I-23 (2.06 g, Yield: 65%) was obtained in the same manner as the synthesis of Intermediate I-21 of Synthesis Example 24, except that Intermediate I-23 and 4-bromophenyl boronic acid, instead of 6,12-dibromochrysene and 3-pyridine boronic acid, respectively, were used. This compound was identified using LC-MS.
  • C30H19Br: M+ 458.1
  • Synthesis of Intermediate I-25
  • Intermediate I-25 (1.61 g, Yield: 71%) was obtained in the same manner as in the synthesis of Intermediate I-23, except that intermediate I-24 instead of Intermediate I-21 was used. This compound was identified using LC-MS.
  • C36H31BO2: M+ 506.2
  • Synthesis of Compound 13B
  • Compound 13B (1.87 g, Yield: 79%) was obtained in the same manner as in the synthesis of Compound 16An of Synthesis Example 3, except that Intermediate I-20 and Intermediate I-25, instead of Intermediate I-10 and Intermediate I-11, respectively, were used. This compound was identified using MS/FAB and 1H NMR.
  • C47H27NO cal. 621.21. found 621.20.
  • Synthesis Example 26 Synthesis of Compound 38B
  • Figure US20150270498A1-20150924-C00176
  • Synthesis of Intermediate I-26
  • Intermediate I-26 (2.77 g, Yield: 64%) was obtained in the same manner as in the synthesis of Intermediate I-21 of Synthesis Example 24, except that 1-naphthylboronic acid instead of 3-pyridine boronic acid was used This compound was identified using LC-MS.
  • C28H17Br: M+ 432.0
  • Synthesis of Intermediate I-27
  • Intermediate I-27 (2.30 g, Yield: 75%) was obtained in the same manner as in the synthesis of Intermediate I-22 of Synthesis Example 24, except that intermediate I-26 instead of Intermediate I-21 was used. This compound was identified using LC-MS.
  • C34H29BO2: M+ 480.2
  • Synthesis of Compound 38B
  • Compound 38B (2.17 g, Yield: 76%) was obtained in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-27, instead of 1-pyrene boronic acid, was used. This compound was identified using MS/FAB and 1H NMR.
  • C45H25NO cal. 595.19. found 595.20.
  • Synthesis Example 27 Synthesis of Compound 22B
  • Compound 22B was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-20 and Intermediate I-22B, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Synthesis Example 28 Synthesis of Compound 32B
  • Compound 32B was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-20 and Intermediate I-32B, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Synthesis Example 29 Synthesis of Compound 42B
  • Compound 42B was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-42B instead of 1-pyrene boronic acid was used.
  • Synthesis Example 30 Synthesis of Compound 54B
  • Compound 54B was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-54B instead of 1-pyrene boronic acid was used.
  • Synthesis Example 31 Synthesis of Compound 64B
  • Compound 64B was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-64B instead of 1-pyrene boronic acid was used.
  • Synthesis Example 32 Synthesis of Compound 79B
  • Compound 79B was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-13 and Intermediate I-79B, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Synthesis Example 33 Synthesis of Compound 85B
  • Compound 85A was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-10 and Intermediate I-79B, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Synthesis Example 34 Synthesis of Compound 91B
  • Compound 91B was synthesized in the same manner as in the synthesis of Compound 1A of Synthesis Example 1, except that Intermediate I-29 and Intermediate I-79B, instead of Intermediate I-4 and 1-pyrene boronic acid, respectively, were used.
  • Figure US20150270498A1-20150924-C00177
    Figure US20150270498A1-20150924-C00178
    Figure US20150270498A1-20150924-C00179
    Figure US20150270498A1-20150924-C00180
    Figure US20150270498A1-20150924-C00181
    Figure US20150270498A1-20150924-C00182
    Figure US20150270498A1-20150924-C00183
    Figure US20150270498A1-20150924-C00184
    Figure US20150270498A1-20150924-C00185
    Figure US20150270498A1-20150924-C00186
    Figure US20150270498A1-20150924-C00187
  • 1H NMR and MS/FAB data of the synthesized compounds are shown in Table 1.
  • TABLE 1
    MS/FAB
    Compound 1H NMR (CDCl3, 400 MHz) found calc.
     1A δ = 8.42-8.40 (m, 1H), 8.26-8.25 (m, 1H), 8.24-8.23 (m, 443.14 443.13
    1H), 8.21-8.20 (m, 2H), 8.18-8.16 (m, 2H), 8.09-8.07
    (m, 1H), 8.04-8.02 (m, 1H), 7.91-7.88 (m, 2H),
    7.69-7.67 (m, 1H), 7.65-7.62 (m, 2H), 7.58-7.54 (m, 1H),
    7.50-7.48 (m, 1H), 7.22-7.20 (m, 1H)
     3A δ = 8.63-8.59 (m, 2H), 8.46-8.44 (m, 1H), 8.31-8.26 (m, 520.15 520.16
    4H), 8.19-8.17 (m, 1H), 8.05-8.02 (m, 2H), 7.95-7.93
    (m, 1H), 7.90-7.88 (m, 1H), 7.84-7.79 (m, 1H),
    7.71-7.68 (m, 1H), 7.66-7.63 (m, 2H), 7.58-7.54 (m, 1H),
    7.50-7.48 (m, 1H), 7.36-7.33 (m, 1H), 7.21-7.19 (m,
    1H)
    16A δ = 8.48-8.46 (m, 1H), 8.33-8.31 (m, 1H), 8.28-8.25 (m, 569.20 569.18
    2H), 8.23-8.22 (m, 1H), 8.21-8.20 (m, 1H), 8.16-8.11
    (m, 4H), 8.08-8.05 (m, 2H), 7.97-7.94 (m, 1H),
    7.91-7.87 (m, 3H), 7.84-7.79 (m, 2H), 7.64-7.51 (m, 3H),
    7.32-7.31 (dd, 1H), 7.26-7.24 (m, 1H)
    20A δ = 8.60-8.59 (dd, 2H), 8.56 (d, 2H), 8.49-8.47 (m, 1H), 673.21 673.22
    8.45-8.40 (m, 2H), 8.24-8.23 (m, 1H), 8.22-8.21 (m,
    1H), 8.16-8.14 (m, 1H), 8.12-8.10 (m, 3H), 8.08-8.05
    (m, 2H), 7.98-7.94 (m, 2H), 7.76-7.71 (m, 2H),
    7.66-7.57 (m, 4H), 7.32-7.28 (m, 3H), 7.24-7.22 (dd, 1H)
    24A δ = 8.33-8.30 (m, 1H), 8.29-8.27 (m, 1H), 8.26-8.23 (m, 519.17 519.16
    2H), 8.21-8.17 (m, 4H), 8.12-8.10 (m, 1H), 8.05-8.02
    (m, 3H), 7.66-7.65 (m, 1H), 7.63-7.61 (m, 2H),
    7.51-7.46 (m, 3H), 7.38-7.31 (m, 2H), 7.27-7.25 (m, 1H)
    32A δ = 8.69 (d, 1H), 8.54-8.53 (m, 2H), 8.30-8.27 (m, 2H), 673.23 673.22
    8.25-8.24 (m, 1H), 8.18-8.12 (m, 2H), 8.05-8.02 (m,
    4H), 7.98-7.96 (m, 1H), 7.92-7.88 (m, 2H), 7.80-7.70
    (m, 5H), 7.65-7.62 (m, 4H), 7.55-7.50 (m, 2H),
    7.22-7.20 (dd, 1H)
    39A δ = 8.63-8.59 (m, 2H), 8.55-8.52 (dd, 1H), 8.31-8.28 (m, 596.21 596.19
    2H), 8.26-8.25 (m, 1H), 8.16-8.08 (m, 4H), 8.03 (d, 1H),
    7.95-7.93 (m, 1H), 7.84-7.79 (m, 4H), 7.75-7.62 (m,
    4H), 7.46-7.43 (dd, 1H), 7.32-7.26 (m, 2H), 7.20-7.18
    (m, 1H)
    46A δ = 8.69 (d, 1H), 8.39-8.37 (m, 1H), 8.33-8.26 (m, 6H), 749.24 749.25
    8.18-8.11 (m, 3H), 8.08-8.06 (m, 1H), 8.01-7.95 (m,
    5H), 7.87-7.83 (m, 2H), 7.76-7.71 (m, 2H), 7.65-7.61
    (m, 2H), 7.53-7.48 (m, 4H), 7.44-7.43 (m, 1H),
    7.31-7.27 (m, 2H), 7.24-7.22 (dd, 1H)
    51A δ = 8.33-8.27 (m, 2H), 8.25-8.19 (m, 5H), 8.14-8.11 (m, 645.23 645.21
    2H), 8.04-8.02 (m, 1H), 7.88 (t, 1H), 7.84-7.80 (m, 2H),
    7.68-7.61 (m, 7H), 7.59-7.57 (m, 1H), 7.55-7.51 (m,
    2H), 7.34-7.27 (m, 2H), 7.22-7.20 (m, 1H), 7.12-7.09
    (m, 1H)
    55A δ = 8.79-8.77 (m, 1H), 8.54-8.52 (m, 1H), 8.41-8.36 (m, 646.19 646.20
    2H), 8.32-8.31 (m, 1H), 8.29-8.21 (m, 6H), 8.12 (d, 1H),
    8.07-8.01 (m, 4H), 7.93-7.82 (m, 4H), 7.66-7.63 (m,
    2H), 7.60-7.53 (m, 2H), 7.48-7.45 (m, 1H), 7.20-7.18
    (m, 1H)
    62A δ = 8.82 (d, 1H), 8.68 (d, 1H), 8.50-8.48 (dd, 1H), 646.21 646.20
    8.31-8.22 (m, 4H), 8.14-8.11 (m, 1H), 8.08-8.04 (m, 2H),
    8.01-7.92 (m, 3H), 7.84-7.80 (m, 2H), 7.69-7.59 (m,
    7H), 7.52-7.51 (m, 1H), 7.31-7.24 (m, 2H), 7.11-7.08
    (m, 1H)
    66A δ = 8.51-8.49 (m, 1H), 8.34-8.33 (m, 2H), 8.31-8.30 (m, 695.23 695.22
    1H), 8.29-8.28 (m, 1H), 8.26-8.25 (m, 2H), 8.23-8.21
    (m, 2H), 8.13-8.12 (m, 1H), 8.11-8.10 (m, 2H),
    8.08-7.99 (m, 3H), 7.96-7.94 (m, 1H), 7.91-7.88 (m, 3H),
    7.84-7.83 (m, 1H), 7.82-7.79 (m, 2H), 7.64-7.54 (m,
    5H), 7.44-7.43 (dd, 1H), 7.26-7.24 (m, 1H)
    72A δ = 8.42-8.41 (m, 2H), 8.33-8.32 (m, 2H), 8.04-8.02 (m, 519.15 519.16
    1H), 8.00-7.99 (m, 4H), 7.93-7.91 (m, 1H), 7.88-7.86
    (m, 1H), 7.72-7.69 (m, 2H), 7.65-7.63 (m, 2H),
    7.60-7.54 (m, 2H), 7.45-7.40 (m, 3H), 7.22-7.20 (m, 1H)
    76A δ = 8.53-8.52 (m, 2H), 8.32-8.31 (m, 2H), 8.24-8.22 (m, 596.18 596.19
    2H), 8.17-8.11 (m, 4H), 8.04-8.02 (m, 1H), 7.93-7.86
    (m, 2H), 7.74-7.69 (m, 3H), 7.66-7.63 (m, 2H),
    7.60-7.54 (m, 2H), 7.51-7.47 (m, 2H), 7.42-7.38 (m, 1H),
    7.21-7.19 (m, 1H)
    81A δ = 8.98-8.97 (m, 2H), 8.68-8.66 (m, 4H), 8.45-8.41 (m 674.22 674.21
    4H), 8.33 (s, 2H), 8.21-8.19 (dd, 1H), 8.04-8.02 (dd,
    1H), 7.66-7.61 (m, 3H), 7.55-7.51 (m, 5H), 7.45-7.37
    (m, 3H), 7.21 (d, 1H)
    85A δ = 8.55-8.52 (m, 1H), 8.40-8.39 (m, 2H), 8.36-8.35 (m, 569.20 569.18
    2H), 8.21-8.20 (dd, 1H), 8.11-8.08 (m, 1H), 8.03-8.00
    (m, 4H), 7.92-7.90 (m, 1H), 7.83-7.77 (m, 2H),
    7.69-7.61 (m, 3H), 7.57-7.48 (m, 2H), 7.30-7.19 (m, 3H),
    7.10-7.09 (dd, 1H)
    94A δ = 8.50-8.49 (m, 2H), 8.47-8.45 (dd, 1H), 8.40-8.39 (m, 569.19 569.18
    2H), 8.23-8.22 (m, 1H), 8.08-8.05 (m, 1H), 8.03-8.01
    (dd, 1H), 7.99-7.98 (m, 4H), 7.96-7.93 (m, 3H),
    7.87-7.82 (m, 2H), 7.66-7.56 (m, 3H), 7.52-7.48 (m, 1H),
    7.42-7.41 (m, 1H), 7.26-7.24 (m, 1H)
    109A  δ = 8.44-8.42 (m, 4H), 8.08-8.06 (m, 1H), 8.01-7.96 (m, 645.23 645.21
    7H), 7.92-7.86 (m, 3H), 7.79-7.67 (m, 6H), 7.57-7.48
    (m, 2H), 7.43-7.42 (m, 1H), 7.28-7.19 (m, 3H)
    113A  δ = 8.89-8.87 (dd, 1H), 8.43-8.42 (m, 4H), 8.38-8.36 (dd, 722.25 722.24
    1H), 8.20-8.18 (dd, 1H), 8.12-8.10 (dd, 1H), 8.08-8.06
    (m, 1H), 8.01-7.98 (m, 7H), 7.90-7.81 (m, 4H),
    7.77-7.71 (m, 6H), 7.60-7.56 (m, 1H), 7.47-7.43 (m, 2H),
    7.24-7.22 (m, 1H)
    119A  δ = 8.57-8.56 (m, 2H), 8.49-8.48 (m, 2H), 8.24-8.23 (m, 672.21 672.22
    1H), 8.21-8.20 (m, 1H), 8.14-8.08 (m, 4H), 8.04-8.02
    (m, 1H), 7.91-7.84 (m, 4H), 7.76-7.69 (m, 4H),
    7.66-7.63 (m, 2H), 7.60-7.56 (m, 1H), 7.53-7.47 (m, 4H),
    7.42-7.38 (m, 1H), 7.21-7.19 (m, 1H)
    123A  δ = 8.99-8.98 (m, 1H), 8.61-8.59 (m, 1H), 8.50 (d, 1H), 646.19 646.20
    8.43-8.42 (m, 2H), 8.40-8.39 (m, 2H), 8.10-8.08 (m,
    2H), 8.05-7.99 (m, 4H), 7.86 (d, 1H), 7.77-7.75 (m, 1H),
    7.72-7.63 (m, 5H), 7.58-7.54 (m, 1H), 7.50-7.48 (m,
    1H), 7.44-7.41 (m, 1H), 7.25-7.23 (dd, 1H), 7.19-7.12
    (m, 2H)
    128A  δ = 8.50-8.49 (m, 2H), 8.42-8.41 (m, 2H), 8.26-8.25 (m, 645.22 645.21
    1H), 8.09-8.08 (m, 1H), 8.06-8.05 (m, 1H), 8.02-7.94
    (m, 9H), 7.76-7.70 (m, 4H), 7.60-7.57 (m, 2H),
    7.44-7.40 (m, 4H), 7.25-7.23 (m, 1H)
    131A  δ = 8.56-8.54 (dd, 1H), 8.45-8.44 (m, 4H), 8.24-8.23 (m, 645.23 645.21
    1H), 8.15-8.14 (dd, 1H), 8.12-8.08 (m, 2H), 8.00-7.99
    (m, 4H), 7.96-7.93 (m, 3H), 7.87-7.80 (m, 3H),
    7.73-7.69 (m, 2H), 7.66-7.64 (m, 1H), 7.60-7.56 (m, 1H),
    7.52-7.48 (m, 1H), 7.42-7.40 (dd, 1H), 7.28-7.26 (dd,
    1H), 7.15-7.13 (dd, 1H)
     3B δ = 8.88-8.87 (m, 1H), 8.75-8.73 (m, 1H), 8.71-8.69 (m, 546.16 546.17
    1H), 8.64-8.63 (m, 1H), 8.50-8.47 (m, 2H), 8.09-8.02
    (m, 3H), 7.98-7.94 (m, 2H), 7.89-7.86 (m, 1H),
    7.76-7.65 (m, 5H), 7.50-7.41 (m, 3H), 7.26-7.22 (m, 2H)
    13B δ= 8.72-8.71 (m, 1H), 8.70-8.69 (m, 1H), 8.62-8.61 (m, 621.20 621.21
    1H), 8.52-8.51 (m, 1H), 8.08-8.04 (m, 3H), 7.99-7.95
    (m, 3H), 7.90-7.87 (m, 2H), 7.83-7.81 (dd, 1H),
    7.76-7.65 (m, 5H), 7.62-7.59 (m, 2H), 7.49-7.36 (m, 6H),
    7.26-7.24 (dd, 1H)
    22B δ = 9.23-9.22 (m, 1H), 9.06-9.05 (m, 1H), 8.95-8.90 (m, 776.28 776.26
    2H), 8.70-8.68 (m, 4H), 8.55-8.53 (m, 1H), 8.08-8.05
    (dd, 1H), 7.98-7.95 (m, 3H), 7.90-7.86 (m, 2H),
    7.83-7.65 (m, 6H), 7.62-7.60 (m, 2H), 7.55-7.51 (m, 4H),
    7.45-7.38 (m, 4H), 7.25-7.23 (dd, 1H)
    32B δ = 9.11-9.10 (m, 1H), 8.82-8.80 (m, 1H), 8.68-8.66 (m, 595.21 595.19
    1H), 8.33-8.31 (m, 1H), 8.08-8.06 (dd, 1H), 8.04-8.02
    (m, 1H), 7.98-7.91 (m, 5H), 7.76-7.71 (m, 2H),
    7.68-7.59 (m, 6H), 7.51-7.49 (m, 1H), 7.40-7.38 (m, 1H),
    7.31-7.30 (m, 1H), 7.26-7.24 (dd, 1H), 7.11-7.06 (m,
    2H)
    38B δ = 9.18-9.17 (m, 1H), 9.04-9.03 (m, 1H), 8.81-8.79 (m, 595.20 595.19
    2H), 8.07-8.04 (m, 1H), 7.98-7.96 (m, 1H), 7.86-7.76
    (m, 3H), 7.72-7.48 (m, 11H), 7.43-7.40 (m, 2H),
    7.32-7.28 (m, 1H), 7.17 (d, 1H), 7.11-7.08 (m, 1H)
    42B δ = 9.20-9.19 (m, 1H), 8.89-8.87 (m, 1H), 8.76-8.72 (m, 672.21 672.22
    3H), 8.38-8.36 (dd, 1H), 8.20-8.18 (dd, 1H), 8.12-8.10
    (dd, 1H), 8.05-7.99 (m, 3H), 7.95-7.93 (m, 1H),
    7.83-7.56 (m, 11H), 7.50-7.38 (m, 4H), 7.19-7.17 (m, 1H)
    54B δ = 9.10-9.09 (m, 1H), 8.88-8.86 (m, 1H), 8.83-8.81 (m, 775.24 775.26
    1H), 8.77-8.76 (m, 1H), 8.68 (d, 2H), 8.66-8.65 (m, 2H),
    8.44 (t, 1H), 8.19-8.16 (dd, 1H), 8.05-8.02 (m, 1H),
    7.98-7.96 (m, 1H), 7.92-7.90 (m, 1H), 7.83-7.81 (m,
    1H), 7.70-7.52 (m, 14H), 7.47-7.38 (m, 2H), 7.32-7.29
    (m, 2H), 7.15-7.13 (dd, 1H)
    64B δ = 8.86-8.80 (m, 2H), 8.68-8.67 (m, 1H), 8.64-8.63 (m, 671.21 671.22
    1H), 8.33-8.32 (m, 1H), 8.25-8.24 (m, 1H), 8.05-8.00
    (m, 5H), 7.95-7.93 (m, 1H), 7.91-7.86 (m, 411),
    7.75-7.73 (m, 1H), 7.69-7.63 (m, 4H), 7.60-7.56 (m, 1H),
    7.53-7.36 (m, 6H), 7.14-7.12 (dd, 1H)
    79B δ = 8.99-8.98 (m, 1H), 8.83-8.79 (m, 3H), 8.05-8.02 (m, 671.23 671.22
    1H), 7.98-7.96 (m, 1H), 7.92-7.90 (m, 1H), 7.86-7.81
    (m, 2H), 7.72-7.61 (m, 11H), 7.57-7.50 (m, 4H),
    7.43-7.38 (m, 2H), 7.31-7.27 (m, 1H), 7.14-7.08 (m, 2H)
    85B δ = 8.81-8.80 (m, 1H), 8.79-8.78 (m, 1H), 8.72-8.70 (m, 621.19 621.21
    1H), 8.65-8.64 (m, 1H), 8.17-8.16 (m, 1H), 8.05-8.03
    (m, 2H), 7.98-7.94 (m, 3H), 7.90-7.87 (m, 2H),
    7.84-7.82 (m, 1H), 7.75-7.73 (m, 1H), 7.69-7.60 (m, 6H),
    7.57-7.53 (m, 2H), 7.49-7.44 (m, 2H), 7.42-7.38 (m,
    3H)
    91B δ = 8.82-8.81 (m, 1H), 8.80-8.79 (m, 1H), 8.74-8.73 (m, 621.20 621.21
    1H), 8.66-8.65 (m, 1H), 8.63-8.61 (dd, 1H), 8.14-8.13
    dd, 1H), 8.11-8.08 (m, 1H), 8.06-8.03 (m, 2H),
    7.85-7.80 (m, 4H), 7.75-7.64 (m, 6H), 7.48-7.36 (m, 6H),
    7.28-7.26 (m, 1H), 7.19-7.17 (m, 1H)
  • Example 1
  • A corning 15 Ω/cm2 (1200 Å) ITO glass substrate was cut to a size of 50 mm×50 mm×0.7 mm and then sonicated in isopropyl alcohol and pure water each for five minutes, and then cleaned by irradiation of ultraviolet rays for 30 minutes and exposure to ozone. The resulting ITO glass substrate was mounted into a vacuum deposition device.
  • After 2-TNATA was vacuum-deposited on the ITO anode of the ITO glass substrate to form an HIL having a thickness of 600 Å, NPB was deposited on the HIL to form a HTL having a thickness of about 300 Å, and then DNA (host) and DPAVBi (dopant) were co-deposited in a weight ratio of 98:2 on the HTL to form an EML having a thickness of about 300 Å.
  • Then, Compound 1A was deposited on the EML to form an ETL having a thickness of about 300 Å, and then LiF was deposited on the ETL to form an EIL having a thickness of about 10 Å. Then, Al was deposited on the EIL to form a cathode having a thickness of about 3000 Å, thereby completing the manufacture of an organic light-emitting device.
  • Example 2
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 3A instead of Compound 1A was used to form the ETL.
  • Example 3
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 16A instead of Compound 1A was used to form the ETL.
  • Example 4
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 24A instead of Compound 1A was used to form the ETL.
  • Example 5
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 39A instead of Compound 1A was used to form the ETL.
  • Example 6
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 51A instead of Compound 1A was used to form the ETL.
  • Example 7
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 62A instead of Compound 1A was used to form the ETL.
  • Example 8
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 72A instead of Compound 1A was used to form the ETL.
  • Example 9
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 81A instead of Compound 1A was used to form the ETL.
  • Example 10
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 113A instead of Compound 1A was used to form the ETL.
  • Example 11
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 3B instead of Compound 1A was used to form the ETL.
  • Example 12
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 13B instead of Compound 1A was used to form the ETL.
  • Example 13
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 38B instead of Compound 1A was used to form the ETL.
  • Example 14
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound 79B instead of Compound 1A was used to form the ETL.
  • Comparative Example 1
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Alq3 instead of Compound 1A was used to form the ETL.
  • Figure US20150270498A1-20150924-C00188
  • Comparative Example 2
  • An organic light-emitting device was manufactured in the same manner as in Example 1, except that Compound A instead of Compound 1 was used to form the ETL.
  • Figure US20150270498A1-20150924-C00189
  • Evaluation Example 1
  • Driving voltages, current densities, luminances, efficiencies, and half-lifetimes of the organic light-emitting devices of Examples 1 to 14 and Comparative Examples 1 and 2 were evaluated using a Kethley Source-Measure Unit (SMU 236) and a PR650 (Spectroscan) Source Measurement Unit. (available from Photo Research, Inc.). The results are shown in Table 2 below. A half-lifetime was measured as the time taken until a measured initial luminance (assumed as 100%) is reduced to 50%.)
  • TABLE 2
    Half-
    Driving Current lifetime
    voltage density Luminance Efficiency Emission (hr
    Example ETL (V) (mA/cm2) (cd/m2) (cd/A) color @100 mA/cm2)
    Example 1 Compound 5.48 50 3215 6.43 Blue 421
    1A
    Example 2 Compound 5.15 50 3290 6.58 Blue 437
    3A
    Example 3 Compound 5.31 50 3235 6.47 Blue 466
    16A
    Example 4 Compound 5.33 50 3200 6.40 Blue 433
    24A
    Example 5 Compound 5.25 50 3275 6.55 Blue 417
    39A
    Example 6 Compound 5.42 50 3105 6.21 Blue 395
    51A
    Example 7 Compound 5.26 50 3230 6.46 Blue 438
    62A
    Example 8 Compound 5.19 50 3090 6.18 Blue 441
    72A
    Example 9 Compound 5.24 50 3255 6.51 Blue 425
    81A
    Example Compound 5.38 50 3130 6.26 Blue 412
    10 113A
    Example Compound 4.97 50 3285 6.57 Blue 462
    11 3B
    Example Compound 5.26 50 3195 6.39 Blue 507
    12 13B
    Example Compound 5.13 50 3470 6.94 Blue 516
    13 38B
    Example Compound 5.58 50 3085 6.17 Blue 481
    14 79B
    Comparative Alq3 7.35 50 2065 4.13 Blue 145
    Example 1
    Comparative Compound A 5.67 50 2975 5.95 Blue 293
    Example 2
  • Referring to Table 1, the organic light-emitting devices of Examples 1 to 14 were found to have lower driving voltages, improved current densities, improved luminances, improved efficiencies, and improved half-lifetimes, compared to those of the organic light-emitting devices of Comparative Examples 1 and 2.
  • As described above, according to the one or more of the above embodiments of the present disclosure, an organic light-emitting device including a condensed cyclic compound of Formula 1 above may have a low driving voltage, a high efficiency, a high luminance, and a long lifetime.
  • It should be understood that the example embodiments described therein should be considered in a descriptive sense only and not for purposes of limitation.
  • Descriptions of features or aspects within each embodiment should typically be considered as available for other similar features or aspects in other embodiments.
  • While one or more embodiments of the present disclosure have been described with reference to the FIGURES, it will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present disclosure as defined by the following claims.

Claims (20)

What is claimed is:
1. A compound represented by Formula 1A or 1B:
Figure US20150270498A1-20150924-C00190
wherein, in Formulae 1A and 1B,
X1 is O or S;
L1 is selected from a substituted or unsubstituted C3-C10 cycloalkylene group, a substituted or unsubstituted C2-C10 heterocycloalkylene group, a substituted or unsubstituted C3-C10 cycloalkenylene group, a substituted or unsubstituted C2-C10 heterocycloalkenylene group, a substituted or unsubstituted C6-C60 arylene group, a substituted or unsubstituted C2-C60 heteroarylene group, a substituted or unsubstituted divalent nonaromatic condensed polycyclic group, and a substituted or unsubstituted divalent nonaromatic condensed heteropolycyclic group;
a1 is selected from 0, 1, 2, and 3;
R1 to R22 are each independently selected from a group represented by Formula 2-1, a group represented by Formula 2-2, a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C1-C60 alkyl group, a substituted or unsubstituted C2-C60 alkenyl group, a substituted or unsubstituted C2-C60 alkynyl group, a substituted or unsubstituted C1-C60 alkoxy group, a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C2-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, a substituted or unsubstituted C2-C10 heterocycloalkenyl group, a substituted or unsubstituted C6-C60 aryl group, a substituted or unsubstituted C6-C60 aryloxy group, a substituted or unsubstituted C6-C60 arylthio group, a substituted or unsubstituted C2-C60 heteroaryl group, a substituted or unsubstituted monovalent nonaromatic condensed polycyclic group, a substituted or unsubstituted monovalent nonaromatic condensed heteropolycyclic group, —N(Q1)(Q2), —Si(Q3)(Q4)(Q5), and —B(Q6)(Q7);
at least one of R1 to R10 is a group represented by Formula 2-1 or 2-2, and at least one of R11 to R22 is a group represented by Formula 2-1 or 2-2;
Figure US20150270498A1-20150924-C00191
b1 is an integer selected from 1 to 3;
b2 is an integer selected from 1 to 5; and
* in Formulae 2-1 and 2-2 is a binding site with a core represented by Formula 1A or Formula 1B;
wherein at least one substituent of the substituted C3-C10 cycloalkylene group, the substituted C2-C10 heterocycloalkylene group, the substituted C3-C10 cycloalkenylene group, the substituted C2-C10 heterocycloalkenylene group, the substituted C6-C60 arylene group, the substituted C2-C60 heteroarylene group, the substituted divalent nonaromatic condensed polycyclic group, the substituted divalent nonaromatic condensed heteropolycyclic group, the substituted C1-C60 alkyl group, the substituted C2-C60 alkenyl group, the substituted C2-C60 alkynyl group, the substituted C1-C60 alkoxy group, the substituted C3-C10 cycloalkyl group, the substituted C2-C10 heterocycloalkyl group, the substituted C3-C10cycloalkenyl group, the substituted C2-C10 heterocyclolalkenyl group, the substituted C6-C60 aryl group, the substituted C6-C60 aryloxy group, the substituted C6-C60 arylthio group, the substituted C2-C60 heteroaryl group, the substituted monovalent nonaromatic condensed polycyclic group, and the substituted monovalent nonaromatic condensed heteropolycyclic group is selected from
a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, and a C1-C60 alkoxy group,
a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, and a C1-C60 alkoxy group, each substituted with at least one of a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C10 cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C2-C60 heteroaryl group, a monovalent nonaromatic condensed polycyclic group, a monovalent nonaromatic condensed heteropolycyclic group, —N(Q11)(Q12), —Si(Q13)(Q14)(Q15), and —B(Q16)(Q17),
a C3-C10cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C2-C60 heteroaryl group, a monovalent nonaromatic condensed polycyclic group, and a monovalent nonaromatic condensed heteropolycyclic group,
a C3-C10 cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C2-C60 heteroaryl group, a monovalent nonaromatic condensed polycyclic group, and a monovalent nonaromatic condensed heteropolycyclic group, each substituted with at least one of a deuterium atom, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C10cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C6r aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C2-C60 heteroaryl group, a monovalent nonaromatic condensed polycyclic group, a monovalent nonaromatic condensed heteropolycyclic group, —N(Q21)(Q22), —Si(Q23)(Q24)(Q25), and —B(Q26)(Q27), —N(Q31)(Q32), —Si(Q33)(Q34)(Q35), and —B(Q36)(Q37),
wherein R31, R32, Q1 to Q7, Q11 to Q17, Q21 to Q27, and Q31 to Q37 are each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C10 cycloalkyl group, a C2-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C2-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C2-C60 heteroaryl group, a monovalent nonaromatic condensed polycyclic group, and a monovalent aromatic condensed heteropolycyclic group.
2. The compound of claim 1, wherein, in Formulae 2-1 and 2-2, L1 is selected from
a phenylene group, a pentalenylene group, an indeylene group, a naphthylene group, an azulenylene group, a heptalenylene group, an indacenylene group, an acenaphthylene group, a fluorenylene group, a spiro-fluorenylene group, a benzofluorenylene group, a dibenzofluorenylene group, a phenalenylene group, a phenanthrenylene group, an anthracenylene group, a fluoranthenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylene group, a naphthacenylene group, a picenylene group, a perylenylene group, a pentaphenylene group, a hexacenylene group, a pentacenylene group, a rubicenylene group, a coronenylene group, an ovalenylene group, a pyrrolylene group, a thiophenylene group, a furanylene group, an imidazolylene group, a pyrazolylene group, a thiazolylene group, an isothiazolylene group, an oxazolylene group, an isooxazolylene group, a pyridinylene group, a pyrazinylene group, a pyrimidinylene group, a pyridazinylene group, an isoindolylene group, an indolylene group, an indazolylene group, a purinylene group, a quinolinylene group, an isoquinolinylene group, a benzoquinolinylene group, a phthalazinylene group, a naphthyridinylene group, a quinoxalinylene group, a quinazolinylene group, a cinnolinylene group, a carbazolylene group, a phenanthridinylene group, an acridinylene group, a phenanthrolinylene group, a phenazinylene group, a benzoimidazolylene group, a benzofuranylene group, a benzothiophenylene group, an isobenzothiazolylene group, a benzooxazolylene group, an isobenzooxazolylene group, a triazolylene group, a tetrazolylene group, an oxadiazolylene group, a triazinylene group, a dibenzofuranylene group, a dibenzothiophenylene group, a benzocarbazolylene group, a dibenzocarbazolylene group, a thiadiazolyene group, an imidazopyridinylene group, an imidazopyrimidinylene group, a phenylene group, a pentalenylene group, an indeylene group, a naphthylene group, an azulenylene group, a heptalenylene group, an indacenylene group, an acenaphthylene group, a fluorenylene group, a spiro-fluorenylene group, a benzofluorenylene group, a dibenzofluorenylene group, a phenalenylene group, a phenanthrenylene group, an anthracenylene group, a fluoranthenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylene group, a naphthacenylene group, a picenylene group, a perylenylene group, a pentaphenylene group, a hexacenylene group, a pentacenylene group, a rubicenylene group, a coronenylene group, an ovalenylene group, a pyrrolylene group, a thiophenylene group, a furanylene group, an imidazolylene group, a pyrazolylene group, a thiazolylene group, an isothiazolylene group, an oxazolylene group, an isooxazolylene group, a pyridinylene group, a pyrazinylene group, a pyrimidinylene group, a pyridazinylene group, an isoindolylene group, an indolylene group, an indazolylene group, a purinylene group, a quinolinylene group, an isoquinolinylene group, a benzoquinolinylene group, a phthalazinylene group, a naphthyridinylene group, a quinoxalinylene group, a quinazolinylene group, a cinnolinylene group, a carbazolylene group, a phenanthridinylene group, an acridinylene group, a phenanthrolinylene group, a phenazinylene group, a benzoimidazolylene group, a benzofuranylene group, a benzothiophenylene group, an isobenzothiazolylene group, a benzooxazolylene group, an isobenzooxazolylene group, a triazolylene group, a tetrazolylene group, an oxadiazolylene group, a triazinylene group, a dibenzofuranylene group, a dibenzothiophenylene group, a benzocarbazolylene group, a dibenzocarbazolylene group, a thiadiazolyene group, an imidazopyridinylene group, and an imidazopyrimidinylene group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, an a C1-C20 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexenyl group, a phenyl group, a pentalenyl group, an indeyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluorantenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenyl group, a pycenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovalenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isooxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzooxazolyl group, an isobenzooxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a thiadiazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group.
3. The compound of claim 1, wherein L1 in Formulae 2-1 and 2-2 is represented by one of Formulae 3-1 to 3-32:
Figure US20150270498A1-20150924-C00192
Figure US20150270498A1-20150924-C00193
Figure US20150270498A1-20150924-C00194
Figure US20150270498A1-20150924-C00195
Figure US20150270498A1-20150924-C00196
wherein, in Formulae 3-1 to 3-32,
Y1 is O, S, C(Z3)(Z4), N(Z5), or Si(Z6)(Z7);
Z1 to Z7 are each independently selected from a hydrogen, a deuterium, —F, —CI, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino groups, a hydrazine, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group;
d1 is an integer selected from 1 to 4, d2 is an integer selected from 1 to 3, d3 is an integer selected from 1 to 6, d4 is an integer selected from 1 to 8, d5 is 1 or 2, d6 is an integer selected from 1 to 5, and * and *′ are binding sites with adjacent atoms.
4. The compound of claim 1, wherein L1 in Formulae 2-1 and 2-2 is represented by one of Formulae 4-1 to 4-23:
Figure US20150270498A1-20150924-C00197
Figure US20150270498A1-20150924-C00198
Figure US20150270498A1-20150924-C00199
Figure US20150270498A1-20150924-C00200
wherein, in Formulae 4-1 to 4-23, * and *′ are binding sites with adjacent atoms.
5. The compound of claim 1, wherein a1 in Formulae 2-1 and 2-2 is 0 or 1.
6. The compound of claim 1, wherein X1 in Formulae 2-1 and 2-2 is O.
7. The compound of claim 1, wherein at least one substituent of R1 to R10 in Formula 1A, except for the groups represented by Formulae 2-1 and Formula 2-2, and at least one substituent of R11 to R22 in Formula 1B, except for the groups represented by Formulae 2-1 and Formula 2-2, are each independently selected from a substituted or unsubstituted C2-C20 heteroaryl group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group.
8. The compound of claim 1, wherein R1 to R22 are each independently selected from a group represented by Formula 2-1, a group represented by Formula 2-2, a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, and a C1-C20 alkoxy group,
a phenyl group, a pentalenyl group, an indeyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenyl group, a picenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovalenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isooxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzooxazolyl group, an isobenzooxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a thiadiazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group,
a phenyl group, a pentalenyl group, an indeyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluorantenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenyl group, a pycenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovalenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isooxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzooxazolyl group, an isobenzooxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a thiadiazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexenyl group, a phenyl group, a pentalenyl group, an indeyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluorantenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenyl group, a pycenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovalenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isooxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzooxazolyl group, an isobenzooxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a thiadiazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group, and
Si(Q3)(Q4)(Q5), wherein Q3 to Q5 are each independently selected from a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, and a nahthyl group, and
at least one of R1 to R10 is a group represented by Formula 2-1 or Formula 2-2, and at least one of R11 to R22 is a group represented by Formula 2-1 or Formula 2-2.
9. The compound of claim 1, wherein R1 to R22 are each independently selected from
a group represented by Formula 2-1, a group represented by Formulae 2-2, hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, and a C1-C20 alkoxy group,
a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group,
a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group, and
Si(Q3)(Q4)(Q5), wherein Q3 to Q5 are each independently selected from a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, and a nahthyl group; and
at least one of R1 to R10 is a group represented by Formula 2-1 or Formula 2-2, and at least one of R11 to R22 is a group represented by Formula 2-1 or Formula 2-2.
10. The compound of claim 1, wherein R1 or R2 in Formula 1A is a group represented by Formula 2-1 or Formula 2-2, and R22 in Formula 1B is a group represented by Formula 2-1 or Formula 2-2.
11. The compound of claim 1, wherein one of R1 to R10 in Formula 1A is a group represented by Formula 2-1 or Formula 2-2.
12. The compound of claim 1, wherein R1 to R22 are each independently selected from
a group represented by Formula 2-1, a group represented by Formula 2-2, a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, Si(Q3)(Q4)(Q5) (where Q3 to Q5 are each independently selected from a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, and a naphthyl group), and groups represented by Formulae 5-1 to 5-35; and
at least one of R1 to R10 is a group represented by Formula 2-1 or Formula 2-2, and at least one of R11 to R22 is a group represented by Formula 2-1 or Formula 2-2:
Figure US20150270498A1-20150924-C00201
Figure US20150270498A1-20150924-C00202
Figure US20150270498A1-20150924-C00203
Figure US20150270498A1-20150924-C00204
Figure US20150270498A1-20150924-C00205
13. The compound of claim 1, wherein R31 and R32 are each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino groups, a hydrazine, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group.
14. The compound of claim 1, wherein the compound of Formula 1A or 1B is represented by one of Formulae 1A-1 to 1A-4, 1B-1, and 1B-2:
Figure US20150270498A1-20150924-C00206
Figure US20150270498A1-20150924-C00207
wherein, in Formulae 1A-1 to 1A-4, 1B-1, and 1B-2, X1, L1, a1, R6, R7, R16, R31, R32, b1, and b2 are the same as those defined in claim 1.
15. The compound of claim 1, wherein the compound of Formula 1A or 1B is represented by one of Formulae 1A-1(1), 1A-1(2), 1A-2(1), 1A-2(2), 1A-3(1), 1A-3(2), 1A-3(3), 1A-4(1), 1A-4(2), 1B-1(1), 1B-1(2), 1B-1(3), 1B-2(1), and 1B(2):
Figure US20150270498A1-20150924-C00208
Figure US20150270498A1-20150924-C00209
Figure US20150270498A1-20150924-C00210
wherein, in Formulae 1A-1(1), 1A-1(2), 1A-2(1), 1A-2(2), 1A-3(1), 1A-3(2), 1A-3(3), 1A-4(1), 1A-4(2), 1B-1(1), 1B-1(2), 1B-1(3), 1B-2(1), and 1B(2), X1, L1, a1, R6, R7, R31, R32, b1, and b2 are the same as those defined in claim 1.
16. The compound of claim 1, wherein the compound of Formula 1A or 1B is one of Compounds 1A to 133A, and Compounds 1B to 92B:
Figure US20150270498A1-20150924-C00211
Figure US20150270498A1-20150924-C00212
Figure US20150270498A1-20150924-C00213
Figure US20150270498A1-20150924-C00214
Figure US20150270498A1-20150924-C00215
Figure US20150270498A1-20150924-C00216
Figure US20150270498A1-20150924-C00217
Figure US20150270498A1-20150924-C00218
Figure US20150270498A1-20150924-C00219
Figure US20150270498A1-20150924-C00220
Figure US20150270498A1-20150924-C00221
Figure US20150270498A1-20150924-C00222
Figure US20150270498A1-20150924-C00223
Figure US20150270498A1-20150924-C00224
Figure US20150270498A1-20150924-C00225
Figure US20150270498A1-20150924-C00226
Figure US20150270498A1-20150924-C00227
Figure US20150270498A1-20150924-C00228
Figure US20150270498A1-20150924-C00229
Figure US20150270498A1-20150924-C00230
Figure US20150270498A1-20150924-C00231
Figure US20150270498A1-20150924-C00232
Figure US20150270498A1-20150924-C00233
Figure US20150270498A1-20150924-C00234
Figure US20150270498A1-20150924-C00235
Figure US20150270498A1-20150924-C00236
Figure US20150270498A1-20150924-C00237
Figure US20150270498A1-20150924-C00238
Figure US20150270498A1-20150924-C00239
Figure US20150270498A1-20150924-C00240
Figure US20150270498A1-20150924-C00241
Figure US20150270498A1-20150924-C00242
Figure US20150270498A1-20150924-C00243
Figure US20150270498A1-20150924-C00244
Figure US20150270498A1-20150924-C00245
Figure US20150270498A1-20150924-C00246
Figure US20150270498A1-20150924-C00247
Figure US20150270498A1-20150924-C00248
Figure US20150270498A1-20150924-C00249
Figure US20150270498A1-20150924-C00250
Figure US20150270498A1-20150924-C00251
Figure US20150270498A1-20150924-C00252
Figure US20150270498A1-20150924-C00253
Figure US20150270498A1-20150924-C00254
Figure US20150270498A1-20150924-C00255
Figure US20150270498A1-20150924-C00256
Figure US20150270498A1-20150924-C00257
Figure US20150270498A1-20150924-C00258
Figure US20150270498A1-20150924-C00259
Figure US20150270498A1-20150924-C00260
Figure US20150270498A1-20150924-C00261
Figure US20150270498A1-20150924-C00262
Figure US20150270498A1-20150924-C00263
Figure US20150270498A1-20150924-C00264
Figure US20150270498A1-20150924-C00265
Figure US20150270498A1-20150924-C00266
Figure US20150270498A1-20150924-C00267
Figure US20150270498A1-20150924-C00268
Figure US20150270498A1-20150924-C00269
Figure US20150270498A1-20150924-C00270
Figure US20150270498A1-20150924-C00271
Figure US20150270498A1-20150924-C00272
Figure US20150270498A1-20150924-C00273
Figure US20150270498A1-20150924-C00274
Figure US20150270498A1-20150924-C00275
Figure US20150270498A1-20150924-C00276
Figure US20150270498A1-20150924-C00277
Figure US20150270498A1-20150924-C00278
Figure US20150270498A1-20150924-C00279
Figure US20150270498A1-20150924-C00280
Figure US20150270498A1-20150924-C00281
Figure US20150270498A1-20150924-C00282
Figure US20150270498A1-20150924-C00283
Figure US20150270498A1-20150924-C00284
Figure US20150270498A1-20150924-C00285
Figure US20150270498A1-20150924-C00286
Figure US20150270498A1-20150924-C00287
Figure US20150270498A1-20150924-C00288
Figure US20150270498A1-20150924-C00289
Figure US20150270498A1-20150924-C00290
Figure US20150270498A1-20150924-C00291
Figure US20150270498A1-20150924-C00292
Figure US20150270498A1-20150924-C00293
Figure US20150270498A1-20150924-C00294
Figure US20150270498A1-20150924-C00295
Figure US20150270498A1-20150924-C00296
Figure US20150270498A1-20150924-C00297
Figure US20150270498A1-20150924-C00298
Figure US20150270498A1-20150924-C00299
Figure US20150270498A1-20150924-C00300
Figure US20150270498A1-20150924-C00301
Figure US20150270498A1-20150924-C00302
Figure US20150270498A1-20150924-C00303
Figure US20150270498A1-20150924-C00304
17. An organic light-emitting device comprising: a first electrode; a second electrode disposed opposite to the first electrode; and an organic layer disposed between the first electrode and the second electrode and comprising an emission layer, wherein the organic layer comprises at least one of the compounds of claim 1.
18. The organic light-emitting device of claim 17, wherein
the first electrode is an anode,
the second electrode is a cathode,
the organic layer comprises i) a hole transport region disposed between the first electrode and the emission layer and comprising at least one of a hole injection layer, a hole transport layer, a buffer layer, and an electron blocking layer, and ii) an electron transport region disposed between the emission layer and the second electrode and comprising at least one of a hole blocking layer, an electron transport layer, and an electron injection layer.
19. The organic light-emitting device of claim 18, wherein the electron transport region comprises the at least one of the compounds of claim 1.
20. The organic light-emitting device of claim 18, wherein the hole transport region comprises at least one of a compound represented by Formula 201A and a compound represented by Formula 202A:
Figure US20150270498A1-20150924-C00305
wherein, in Formulae 201A and 202A,
L201 and L203 are each independently selected from
a phenylene group, a naphthylene group, a fluorenylene group, a spiro-fluorenylene group, a benzofluorenylene group, a dibenzofluorenylene group, a phenanthrenyl group, an anthracenylene group, a pyrenylene group, a chrysenylene group, a pyridinylene group, a pyrazinylene group, a pyrimidinylene group, a pyridazinylene group, a quinolinylene group, an isoquinolinylene group, a quinoxalinylene group, a quinazolinylene group, a carbazolylene group, and a triazinylene group, and
a phenylene group, a naphthylene group, a fluorenylene group, a spiro-fluorenylene group, a benzofluorenylene group, a dibenzofluorenylene group, a phenanthrenyl group, an anthracenylene group, a pyrenylene group, a chrysenylene group, a pyridinylene group, a pyrazinylene group, a pyrimidinylene group, a pyridazinylene group, a quinolinylene group, an isoquinolinylene group, a quinoxalinylene group, a quinazolinylene group, a carbazolylene group, and a triazinylene group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group;
xa1 to xa3 are each independently 0 or 1;
R203, R211, and R212 are each independently selected from
a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group, and
a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group;
R213 and R214 are each independently selected from
a C1-C20 alkyl group and a C1-C20 alkoxy group,
a C1-C20 alkyl group and a C1-C20 alkoxy group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group,
a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group, and
a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group;
R215 and R216 are each independently selected from
a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine, a hydrazone, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, and a C1-C20 alkoxy group,
a C1-C20 alkyl group and a C1-C20 alkoxy group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group,
a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, and a triazinyl group, and
a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a spiro-fluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a pyrenyl group, a chrysenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, and a triazinyl group; and
xa5 is 1 or 2.
US14/558,491 2014-03-19 2014-12-02 Condensed cyclic compound and organic light-emitting device comprising the same Active 2035-10-12 US9831443B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2014-0032165 2014-03-19
KR1020140032165A KR102184675B1 (en) 2014-03-19 2014-03-19 Condensed-cyclic compound and organic light emitting diode comprising the same

Publications (2)

Publication Number Publication Date
US20150270498A1 true US20150270498A1 (en) 2015-09-24
US9831443B2 US9831443B2 (en) 2017-11-28

Family

ID=54142933

Family Applications (1)

Application Number Title Priority Date Filing Date
US14/558,491 Active 2035-10-12 US9831443B2 (en) 2014-03-19 2014-12-02 Condensed cyclic compound and organic light-emitting device comprising the same

Country Status (2)

Country Link
US (1) US9831443B2 (en)
KR (1) KR102184675B1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160163992A1 (en) * 2014-12-08 2016-06-09 Samsung Display Co., Ltd. Organic light emitting device and display device having the same
CN106554319A (en) * 2015-09-30 2017-04-05 北京鼎材科技有限公司 A kind of * analog derivatives containing quinazoline group and its application
KR20190112083A (en) * 2018-03-23 2019-10-02 에스케이머티리얼즈 주식회사 Compounds, Organic Light-Emitting Devices and Display Devices
WO2022091691A1 (en) 2020-10-27 2022-05-05 出光興産株式会社 Compound, organic electroluminescent element and electronic device
US11539000B2 (en) * 2019-10-29 2022-12-27 Wuhan Tianma Micro-Electronics Co., Ltd. Compound, display panel, and display device

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102577003B1 (en) * 2016-06-03 2023-09-12 삼성디스플레이 주식회사 Compound and Organic light emitting device comprising same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2863278B2 (en) 1990-06-29 1999-03-03 京セラ株式会社 Dry developing device
JP3755196B2 (en) 1996-06-28 2006-03-15 チッソ株式会社 Electroluminescent device using cyclopentadiene derivative
US5645948A (en) 1996-08-20 1997-07-08 Eastman Kodak Company Blue organic electroluminescent devices
JP3834954B2 (en) 1997-09-05 2006-10-18 チッソ株式会社 Hole transport material having silacyclopentadiene ring
KR100691543B1 (en) 2002-01-18 2007-03-09 주식회사 엘지화학 New material for transporting electron and organic electroluminescent display using the same
JP4060669B2 (en) 2002-08-28 2008-03-12 富士フイルム株式会社 1,3,6,8-tetrasubstituted pyrene compound, organic EL device and organic EL display
EP1437395B2 (en) 2002-12-24 2015-08-26 LG Display Co., Ltd. Organic electroluminescent device
KR100525408B1 (en) 2002-12-24 2005-11-02 엘지전자 주식회사 organic electroluminescence device
JP2007123863A (en) 2005-09-30 2007-05-17 Chisso Corp Material for light emitting element, and organic electroluminescent element using it
DE102006031990A1 (en) * 2006-07-11 2008-01-17 Merck Patent Gmbh New materials for organic electroluminescent devices
JP2009096771A (en) 2007-10-18 2009-05-07 Mitsubishi Chemicals Corp Diarylpyrene compound, material for organic electroluminescent device, composition for organic electroluminescent device, and organic electroluminescent device
JP2010195708A (en) 2009-02-25 2010-09-09 Toyo Ink Mfg Co Ltd Compound having carbazolyl group and use thereof
JP2011204844A (en) 2010-03-25 2011-10-13 Toray Ind Inc Light emitting device
KR20120051598A (en) 2010-11-12 2012-05-22 주식회사 엘지화학 New compounds and organic electronic device using the same
EP2644607A4 (en) 2010-11-22 2014-05-28 Idemitsu Kosan Co Oxygenated fused ring derivative and organic electroluminescence element containing the same
WO2012157474A1 (en) 2011-05-13 2012-11-22 シャープ株式会社 Compound, field effect transistor, method for manufacturing field effect transistor, solar cell, organic light-emitting element, composition, array for display devices, and display device
KR102191990B1 (en) * 2013-09-10 2020-12-17 삼성디스플레이 주식회사 Condensed compound and organic light emitting diode comprising the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Machine English translation of Kamioka et al. (JP 2011-204844 A). 05/03/17. *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160163992A1 (en) * 2014-12-08 2016-06-09 Samsung Display Co., Ltd. Organic light emitting device and display device having the same
US9991446B2 (en) * 2014-12-08 2018-06-05 Samsung Display Co., Ltd. Organic light emitting device and display device having the same
CN106554319A (en) * 2015-09-30 2017-04-05 北京鼎材科技有限公司 A kind of * analog derivatives containing quinazoline group and its application
KR20190112083A (en) * 2018-03-23 2019-10-02 에스케이머티리얼즈 주식회사 Compounds, Organic Light-Emitting Devices and Display Devices
KR102084906B1 (en) 2018-03-23 2020-03-04 에스케이머티리얼즈 주식회사 Compound, organic light emitting device and display device
CN111683942A (en) * 2018-03-23 2020-09-18 Sk材料有限公司 Compound, organic light emitting device and display device
US11539000B2 (en) * 2019-10-29 2022-12-27 Wuhan Tianma Micro-Electronics Co., Ltd. Compound, display panel, and display device
WO2022091691A1 (en) 2020-10-27 2022-05-05 出光興産株式会社 Compound, organic electroluminescent element and electronic device
KR20230097082A (en) 2020-10-27 2023-06-30 이데미쓰 고산 가부시키가이샤 Compounds, organic electroluminescent devices and electronic devices

Also Published As

Publication number Publication date
US9831443B2 (en) 2017-11-28
KR20150109522A (en) 2015-10-02
KR102184675B1 (en) 2020-12-01

Similar Documents

Publication Publication Date Title
US9871208B2 (en) Condensed cyclic compound and organic light-emitting device including the same
US9899611B2 (en) Condensed cyclic compound and organic light-emitting device including the same
US9876179B2 (en) Organic light emitting device
US9583715B2 (en) Anthracene-based compounds and organic light-emitting device including the same
KR101717551B1 (en) Condensed-cyclic compound and organic light emitting device comprising the same
US9837614B2 (en) Condensed-cyclic compound and organic light-emitting device comprising the same
US9705088B2 (en) Triazine-based compounds and organic light-emitting devices including triazine-based compounds
US9831443B2 (en) Condensed cyclic compound and organic light-emitting device comprising the same
US9537104B2 (en) Condensed-cyclic compound and organic light-emitting diode including the condensed-cyclic compound
US9660197B2 (en) Condensed cyclic compound and organic light-emitting device comprising the same
KR20160053048A (en) Phosphine oxide-based compound and organic light emitting device comprising the same
US9966540B2 (en) Condensed cyclic compound and organic light-emitting device including the same
US10319919B2 (en) Compound and organic light-emitting device including the same
US9601699B2 (en) Chrysene-based compound and organic light-emitting device including the same
US9461261B2 (en) Organic compounds and organic light-emitting devices including the same
US9680106B2 (en) Pyrene-based compound and organic light-emitting device including the same
US9437827B2 (en) Heterocyclic compound and organic light-emitting device including the same
US20160072072A1 (en) Condensed cyclic compound and organic light-emitting device including the same
US10720585B2 (en) Compound and organic light-emitting device including the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: SAMSUNG DISPLAY CO., LTD., KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEE, EUN-YOUNG;KIM, YOUNG-KOOK;PARK, JUN-HA;AND OTHERS;REEL/FRAME:034362/0765

Effective date: 20140723

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4